CA3123732A1 - Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing in the same as an active ingredient - Google Patents
Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing in the same as an active ingredientInfo
- Publication number
- CA3123732A1 CA3123732A1 CA3123732A CA3123732A CA3123732A1 CA 3123732 A1 CA3123732 A1 CA 3123732A1 CA 3123732 A CA3123732 A CA 3123732A CA 3123732 A CA3123732 A CA 3123732A CA 3123732 A1 CA3123732 A1 CA 3123732A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- present
- disease
- formula
- isoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 48
- 201000010099 disease Diseases 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title abstract description 26
- 102000003954 Autophagy-Related Proteins Human genes 0.000 title abstract description 23
- 108010082399 Autophagy-Related Proteins Proteins 0.000 title abstract description 23
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title abstract 5
- 239000004480 active ingredient Substances 0.000 title description 23
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 15
- 230000003061 melanogenesis Effects 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 160
- 150000003839 salts Chemical class 0.000 claims description 32
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 24
- 208000010706 fatty liver disease Diseases 0.000 claims description 21
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 17
- 208000004930 Fatty Liver Diseases 0.000 claims description 16
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 206010040865 Skin hyperpigmentation Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- YIILMDJAIZHXQM-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfinylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2S(=O)C3=CC=C(C=C3)F YIILMDJAIZHXQM-UHFFFAOYSA-N 0.000 claims description 5
- JAFNMZJLUNTQTG-UHFFFAOYSA-N 4-(4-fluorophenyl)sulfinylquinoline Chemical compound C1=CC=C2C(=C1)C(=CC=N2)S(=O)C3=CC=C(C=C3)F JAFNMZJLUNTQTG-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- KWGIANFNNDRUHP-UHFFFAOYSA-N 1-(2,4-difluorophenyl)sulfinylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2S(=O)C3=C(C=C(C=C3)F)F KWGIANFNNDRUHP-UHFFFAOYSA-N 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 4
- 241001420836 Ophthalmitis Species 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 238000012261 overproduction Methods 0.000 claims description 4
- 208000010403 panophthalmitis Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- OTYYBKLEHOEDLV-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfinylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2S(=O)C3=CC=C(C=C3)Cl OTYYBKLEHOEDLV-UHFFFAOYSA-N 0.000 claims description 3
- GHOWRWIPVLOIMI-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]sulfinylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2S(=O)C3=CC=C(C=C3)C(F)(F)F GHOWRWIPVLOIMI-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 239000000203 mixture Substances 0.000 abstract description 43
- 230000004900 autophagic degradation Effects 0.000 abstract description 27
- 238000002360 preparation method Methods 0.000 abstract description 26
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 239000002537 cosmetic Substances 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 10
- 208000030159 metabolic disease Diseases 0.000 abstract description 10
- 230000002087 whitening effect Effects 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 9
- 230000004770 neurodegeneration Effects 0.000 abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 26
- 241000251468 Actinopterygii Species 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 230000000366 juvenile effect Effects 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 22
- 241000252212 Danio rerio Species 0.000 description 19
- -1 cyano, nitro, amino Chemical group 0.000 description 18
- 239000002158 endotoxin Substances 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 230000004720 fertilization Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 16
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 16
- 230000028709 inflammatory response Effects 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 13
- 210000002752 melanocyte Anatomy 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 229960001603 tamoxifen Drugs 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 150000002537 isoquinolines Chemical class 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 101150041968 CDC13 gene Proteins 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 210000004957 autophagosome Anatomy 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 10
- 239000008055 phosphate buffer solution Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 206010067125 Liver injury Diseases 0.000 description 8
- 208000003351 Melanosis Diseases 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 231100000234 hepatic damage Toxicity 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000008818 liver damage Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000008099 melanin synthesis Effects 0.000 description 7
- 230000019612 pigmentation Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000011808 rodent model Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 5
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 5
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000002073 fluorescence micrograph Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- NBJDMDIPZFSYCZ-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfanylisoquinoline Chemical compound FC1=CC=C(C=C1)SC1=NC=CC2=CC=CC=C12 NBJDMDIPZFSYCZ-UHFFFAOYSA-N 0.000 description 4
- MSQCQINLJMEVNJ-UHFFFAOYSA-N 1-chloroisoquinoline Chemical compound C1=CC=C2C(Cl)=NC=CC2=C1 MSQCQINLJMEVNJ-UHFFFAOYSA-N 0.000 description 4
- 102000004072 Beclin-1 Human genes 0.000 description 4
- 108090000524 Beclin-1 Proteins 0.000 description 4
- 206010048610 Cardiotoxicity Diseases 0.000 description 4
- 206010008570 Chloasma Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- 231100000259 cardiotoxicity Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102000014898 transaminase activity proteins Human genes 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 102000014461 Ataxins Human genes 0.000 description 3
- 108010078286 Ataxins Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 102000004321 Atrophin-1 Human genes 0.000 description 3
- 108090000806 Atrophin-1 Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010008025 Cerebellar ataxia Diseases 0.000 description 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 3
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000027747 Kennedy disease Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 206010061137 Ocular toxicity Diseases 0.000 description 3
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010059516 Skin toxicity Diseases 0.000 description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 201000006061 fatal familial insomnia Diseases 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 210000004276 hyalin Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 206010024217 lentigo Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 231100000327 ocular toxicity Toxicity 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 231100000438 skin toxicity Toxicity 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229940072040 tricaine Drugs 0.000 description 3
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ALOFHINOYJOXSV-UHFFFAOYSA-N 1-(2,4-difluorophenyl)sulfanylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2SC3=C(C=C(C=C3)F)F ALOFHINOYJOXSV-UHFFFAOYSA-N 0.000 description 2
- DYUVDKPKMIBUKJ-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfanylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2SC3=CC=C(C=C3)Cl DYUVDKPKMIBUKJ-UHFFFAOYSA-N 0.000 description 2
- UXKSXFBWCJXZOC-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]sulfanylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2SC3=CC=C(C=C3)C(F)(F)F UXKSXFBWCJXZOC-UHFFFAOYSA-N 0.000 description 2
- BICHBFCGCJNCAT-UHFFFAOYSA-N 2,4-difluorobenzenethiol Chemical compound FC1=CC=C(S)C(F)=C1 BICHBFCGCJNCAT-UHFFFAOYSA-N 0.000 description 2
- KGJONGFWQXKEDR-UHFFFAOYSA-N 4-(4-fluorophenyl)sulfanyl-1h-quinolin-2-one Chemical compound C1=CC(F)=CC=C1SC1=CC(=O)NC2=CC=CC=C12 KGJONGFWQXKEDR-UHFFFAOYSA-N 0.000 description 2
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SPJUGAAGCKCNLV-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfonylisoquinoline Chemical compound C1=CC=C2C(=C1)C=CN=C2S(=O)(=O)C3=CC=C(C=C3)F SPJUGAAGCKCNLV-UHFFFAOYSA-N 0.000 description 1
- FYWDEEUCCVRSPL-UHFFFAOYSA-N 1-chloro-2h-quinoline Chemical compound C1=CC=C2N(Cl)CC=CC2=C1 FYWDEEUCCVRSPL-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- WCMLRSZJUIKVCW-UHFFFAOYSA-N 4-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=C(S)C=C1 WCMLRSZJUIKVCW-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002923 anti-melanogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004961 autolysosome Anatomy 0.000 description 1
- 230000007320 autophagy mechanism Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000003372 electrophysiological method Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000009013 pigment accumulation Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000015629 regulation of autophagy Effects 0.000 description 1
- 230000031337 regulation of inflammatory response Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- DQJCHOQLCLEDLL-UHFFFAOYSA-N tricyclazole Chemical compound CC1=CC=CC2=C1N1C=NN=C1S2 DQJCHOQLCLEDLL-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel isoquinoline derivatives of Formula 1, <DIG>
wherein X, Y, Z and R1 can represent various chemical entities.
The isoquinoline derivatives can be used for preventing or treating autophagy related diseases containing the same.The isoquinoline derivatives can also be used for regulating autophagy activity, and thus, by using these derivatives, there is a useful effect that can be used as a pharmaceutical composition for preventing or treating autophagy-related diseases such as neurodegenerative diseases, cancer, metabolic diseases, inflammatory diseases or melanogenesis-related diseases, a health functional food composition for ameliorating thereof, or a cosmetic composition with a whitening function. The present disclosure also relates to methods of preparation and pharmaceutical compositions related to the isoquinoline derivatives.
wherein X, Y, Z and R1 can represent various chemical entities.
The isoquinoline derivatives can be used for preventing or treating autophagy related diseases containing the same.The isoquinoline derivatives can also be used for regulating autophagy activity, and thus, by using these derivatives, there is a useful effect that can be used as a pharmaceutical composition for preventing or treating autophagy-related diseases such as neurodegenerative diseases, cancer, metabolic diseases, inflammatory diseases or melanogenesis-related diseases, a health functional food composition for ameliorating thereof, or a cosmetic composition with a whitening function. The present disclosure also relates to methods of preparation and pharmaceutical compositions related to the isoquinoline derivatives.
Description
Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to a novel isoquinoline derivative, a preparing method thereof, and a pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient.
1. Field of the Invention The present invention relates to a novel isoquinoline derivative, a preparing method thereof, and a pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient.
2. Description of the Related Art Autophagy plays an important role in regulating cellular functions such as survival under starvation, protection from infectious bacteria, and regulation of neuronal decay. Autophagy is an evolutionarily conserved process and is known to be observed in all eukaryotic cells from yeast to mammals.
When autophagy is activated, an autophagosome membrane structure is formed by the atg12-atg5 complex and LC3 aggregation. The cytosolic form of LC3 (LC3-I) is split into the membrane-bound form (LC3-II), and the membrane matures into autophagosome surrounding Date Recue/Date Received 2021-06-30 the component to be degraded. Then, the autophagosome fuses with lysosome to form autolysosome, which causes lysosomal degradation of intracellular components.
Various studies are currently underway to elucidate the complicated molecular mechanisms involved in this process.
Meanwhile, autophagy is associated with various pathological processes such as neurodegenerative diseases, cancer, and melanogenesis. In cancer, autophagy can be associated with various stages, where oxygen and nutrients are limited in growing tumor cells, so autophagy is used for survival until the necessary components are provided by angiogenesis. In this case, autophagy must be inhibited to stop tumor cell survival.
Melanogenesis refers to the formation of melanin, a pigment found in the eyes, skin and hair. Increased autophagosomes are observed in pigmentary disorder patients, and more recent studies have reported that lack of beclin 1 or LC3-I significantly attenuates pigment accumulation. In an in vivo assay, lack of beclin 1 heterozygosity resulted in mouse coat pigmentation defects. Melanogenesis is activated by stimulation of external factors such as UV. Pigmentary disorders (melasma, freckles, age spots, etc.) can be Date Recue/Date Received 2021-06-30 caused by melanogenesis. In this case, autophagy must be inhibited to stop melanin hyperproduction.
As described above, in autophagy-related neurodegenerative diseases, cancer and melanin hyperproduction, it is possible to develop a drug capable of regulating autophagy as a potential drug candidate.
On the other hand, as a Beclin 1 related patent involved in autophagy mechanism, EP 2383294 discloses techniques for treating or diagnosing neurodegenerative diseases using antibodies specific for Beclin 1 phosphorylated at position Thr 119.
Ahn et al. reported that 1-((4-fluorophenyl)thio)isoquinoline exhibits an anti-melanogenic effect (Bioorganic & Medicinal Chemistry Letters 30 (2020) 127201).
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a novel isoquinoline derivative as an active ingredient for providing a drug for regulating autophagy activity.
It is another object of the present invention to provide a method for preparing the isoquinoline derivative.
When autophagy is activated, an autophagosome membrane structure is formed by the atg12-atg5 complex and LC3 aggregation. The cytosolic form of LC3 (LC3-I) is split into the membrane-bound form (LC3-II), and the membrane matures into autophagosome surrounding Date Recue/Date Received 2021-06-30 the component to be degraded. Then, the autophagosome fuses with lysosome to form autolysosome, which causes lysosomal degradation of intracellular components.
Various studies are currently underway to elucidate the complicated molecular mechanisms involved in this process.
Meanwhile, autophagy is associated with various pathological processes such as neurodegenerative diseases, cancer, and melanogenesis. In cancer, autophagy can be associated with various stages, where oxygen and nutrients are limited in growing tumor cells, so autophagy is used for survival until the necessary components are provided by angiogenesis. In this case, autophagy must be inhibited to stop tumor cell survival.
Melanogenesis refers to the formation of melanin, a pigment found in the eyes, skin and hair. Increased autophagosomes are observed in pigmentary disorder patients, and more recent studies have reported that lack of beclin 1 or LC3-I significantly attenuates pigment accumulation. In an in vivo assay, lack of beclin 1 heterozygosity resulted in mouse coat pigmentation defects. Melanogenesis is activated by stimulation of external factors such as UV. Pigmentary disorders (melasma, freckles, age spots, etc.) can be Date Recue/Date Received 2021-06-30 caused by melanogenesis. In this case, autophagy must be inhibited to stop melanin hyperproduction.
As described above, in autophagy-related neurodegenerative diseases, cancer and melanin hyperproduction, it is possible to develop a drug capable of regulating autophagy as a potential drug candidate.
On the other hand, as a Beclin 1 related patent involved in autophagy mechanism, EP 2383294 discloses techniques for treating or diagnosing neurodegenerative diseases using antibodies specific for Beclin 1 phosphorylated at position Thr 119.
Ahn et al. reported that 1-((4-fluorophenyl)thio)isoquinoline exhibits an anti-melanogenic effect (Bioorganic & Medicinal Chemistry Letters 30 (2020) 127201).
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a novel isoquinoline derivative as an active ingredient for providing a drug for regulating autophagy activity.
It is another object of the present invention to provide a method for preparing the isoquinoline derivative.
3 Date Recue/Date Received 2021-06-30 It is another object of the present invention to provide a pharmaceutical composition for preventing or treating autophagy related diseases containing the isoquinoline derivative as an active ingredient.
It is another object of the present invention to provide a pharmaceutical composition for preventing or treating inflammatory or metabolic diseases containing the isoquinoline derivative as an active ingredient.
It is another object of the present invention to provide a pharmaceutical composition for preventing or treating skin hyperpigmentation disease containing the isoquinoline derivative as an active ingredient.
To achieve the above objects, in an aspect of the present invention, the present invention provides a compound represented by formula 1 or a pharmaceutically acceptable salt thereof.
[Formula 1]
z' Y
(R2) _________ n X
(In formula 1, Rl is nonsubstituted or substituted phenyl, wherein the substituted phenyl is substituted with one or more substituents selected from the group
It is another object of the present invention to provide a pharmaceutical composition for preventing or treating inflammatory or metabolic diseases containing the isoquinoline derivative as an active ingredient.
It is another object of the present invention to provide a pharmaceutical composition for preventing or treating skin hyperpigmentation disease containing the isoquinoline derivative as an active ingredient.
To achieve the above objects, in an aspect of the present invention, the present invention provides a compound represented by formula 1 or a pharmaceutically acceptable salt thereof.
[Formula 1]
z' Y
(R2) _________ n X
(In formula 1, Rl is nonsubstituted or substituted phenyl, wherein the substituted phenyl is substituted with one or more substituents selected from the group
4 Date Recue/Date Received 2021-06-30 consisting of hydroxy, cyano, nitro, amino, halogen, and nonsubstituted or substituted straight or branched C1-5 alkyl, wherein the substituted alkyl is substituted with halogen;
R2 is hydroxy, amino, cyano, halogen, C1-3 straight or branched alkyl, or C1-3 straight or branched alkoxy;
n is an integer of 0 - 8;
X and Y are independently CH or N; and Z is sulfinyl or sulfonyl).
In another aspect of the present invention, the present invention provides a preparation method of a compound represented by formula 1 comprising a step of preparing a compound represented by formula 1 from a compound represented by formula 4; as shown in reaction formula 1 below:
[Reaction Formula 1]
,R1 CI
(R2) _______________________ (R2) rY
X n .
X
(In reaction formula 1, Rl, R2, n, X, Y and Z are as defined in formula 1 above).
R2 is hydroxy, amino, cyano, halogen, C1-3 straight or branched alkyl, or C1-3 straight or branched alkoxy;
n is an integer of 0 - 8;
X and Y are independently CH or N; and Z is sulfinyl or sulfonyl).
In another aspect of the present invention, the present invention provides a preparation method of a compound represented by formula 1 comprising a step of preparing a compound represented by formula 1 from a compound represented by formula 4; as shown in reaction formula 1 below:
[Reaction Formula 1]
,R1 CI
(R2) _______________________ (R2) rY
X n .
X
(In reaction formula 1, Rl, R2, n, X, Y and Z are as defined in formula 1 above).
5 Date Recue/Date Received 2021-06-30 In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating autophagy related diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating inflammatory or metabolic diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
In addition, in another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating skin hyperpigmentation disease containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
ADVANTAGEOUS EFFECT
The novel isoquinoline furanone derivative according to the present invention is capable of regulating autophagy activity, and thus, by using this derivative as an active ingredient, there is a useful effect that can be used as a pharmaceutical
In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating inflammatory or metabolic diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
In addition, in another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating skin hyperpigmentation disease containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
ADVANTAGEOUS EFFECT
The novel isoquinoline furanone derivative according to the present invention is capable of regulating autophagy activity, and thus, by using this derivative as an active ingredient, there is a useful effect that can be used as a pharmaceutical
6 Date Recue/Date Received 2021-06-30 composition for preventing or treating autophagy-related diseases such as neurodegenerative diseases, cancer, metabolic diseases, inflammatory diseases or melanogenesis-related diseases, a health functional food composition for ameliorating thereof, or a cosmetic composition with a whitening function.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a set of Western blot diagrams confirming the conversions of LC3-I and LC3-II
according to the treatment of the compound of Example 1 of the present invention at the concentrations of 1, 5, 10, and 20 pM in Raw 264.7 mouse macrophages.
Figure 2 is a set of fluorescence micrographs confirming the changes in autophagosomes observed after the treatment of the compound of Example 1 of the present invention at the concentrations of 5, 10, 20, and 50 pM in Raw 264.7 mouse macrophages under the conditions for inducing inflammatory responses by lipopolysaccharide (LPS) treatment.
Figure 3 is a set of graphs illustrating the effect of the compound of Example 1 on the NO
production and cell viability in LPS-treated Raw 264.7 mouse macrophages.
Figure 4 is a graph illustrating the effect of
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a set of Western blot diagrams confirming the conversions of LC3-I and LC3-II
according to the treatment of the compound of Example 1 of the present invention at the concentrations of 1, 5, 10, and 20 pM in Raw 264.7 mouse macrophages.
Figure 2 is a set of fluorescence micrographs confirming the changes in autophagosomes observed after the treatment of the compound of Example 1 of the present invention at the concentrations of 5, 10, 20, and 50 pM in Raw 264.7 mouse macrophages under the conditions for inducing inflammatory responses by lipopolysaccharide (LPS) treatment.
Figure 3 is a set of graphs illustrating the effect of the compound of Example 1 on the NO
production and cell viability in LPS-treated Raw 264.7 mouse macrophages.
Figure 4 is a graph illustrating the effect of
7 Date Recue/Date Received 2021-06-30 the compound of Example 1 of the present invention on the expression of the inflammatory response-related cytokine IL-6 gene.
Figure 5 is a set of graphs illustrating the effect of the compound of Example 1 of the present invention on the secretion of the inflammatory response-related proteins IL-6 and IL-1p.
Figure 6A is a set of zebrafish juvenile fish photographs confirming the effect of inhibiting melanocyte formation at 22 hours after the treatment of the compound of Example 1 of the present invention in fertilized zebrafish eggs 10 hours after fertilization (32 hours after fertilization).
Figure 6B is a set of zebrafish juvenile fish photographs confirming the effect of inhibiting melanocyte formation at 22 hours after the treatment of the compound of Comparative Example 1 of the present invention in fertilized zebrafish eggs 10 hours after fertilization (32 hours after fertilization).
Figure 6C is a set of zebrafish juvenile fish photographs confirming the effect of inhibiting melanocyte formation at 12 hours after the treatment of the compound of Example 1 of the present invention in fertilized zebrafish eggs 60 hours after
Figure 5 is a set of graphs illustrating the effect of the compound of Example 1 of the present invention on the secretion of the inflammatory response-related proteins IL-6 and IL-1p.
Figure 6A is a set of zebrafish juvenile fish photographs confirming the effect of inhibiting melanocyte formation at 22 hours after the treatment of the compound of Example 1 of the present invention in fertilized zebrafish eggs 10 hours after fertilization (32 hours after fertilization).
Figure 6B is a set of zebrafish juvenile fish photographs confirming the effect of inhibiting melanocyte formation at 22 hours after the treatment of the compound of Comparative Example 1 of the present invention in fertilized zebrafish eggs 10 hours after fertilization (32 hours after fertilization).
Figure 6C is a set of zebrafish juvenile fish photographs confirming the effect of inhibiting melanocyte formation at 12 hours after the treatment of the compound of Example 1 of the present invention in fertilized zebrafish eggs 60 hours after
8 Date Recue/Date Received 2021-06-30 fertilization (72 hours after fertilization).
Figure 7 is a set of general microscope images, fluorescence microscope images and heatmap conversion images observed after the treatment of DMSO, tamoxifen and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization.
Figure 8 is a set of graphs illustrating the results of quantification of liver area (top) and fluorescence intensity (bottom) on the zebrafish juvenile fish images observed after the treatment of DMSO, tamoxifen and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization using ImageJ 1.50i softwear (National Institutes of Health, USA) (The p values are the t-test results for each experimental group compared to the tamoxifen-treated group. *p 0.01, **p 0.001).
Figure 9 is a graph illustrating the cell viability of VERO, HFL-1, L929, NIH 3T3, CHO-K1 and HMV-II cell lines according to the concentration of the compound of Example 1 of the present invention treated.
Figure 10 is a graph illustrating the inhibition of the binding and ion channel opening activity of the hERG channel protein by the compound of Example 1 of
Figure 7 is a set of general microscope images, fluorescence microscope images and heatmap conversion images observed after the treatment of DMSO, tamoxifen and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization.
Figure 8 is a set of graphs illustrating the results of quantification of liver area (top) and fluorescence intensity (bottom) on the zebrafish juvenile fish images observed after the treatment of DMSO, tamoxifen and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization using ImageJ 1.50i softwear (National Institutes of Health, USA) (The p values are the t-test results for each experimental group compared to the tamoxifen-treated group. *p 0.01, **p 0.001).
Figure 9 is a graph illustrating the cell viability of VERO, HFL-1, L929, NIH 3T3, CHO-K1 and HMV-II cell lines according to the concentration of the compound of Example 1 of the present invention treated.
Figure 10 is a graph illustrating the inhibition of the binding and ion channel opening activity of the hERG channel protein by the compound of Example 1 of
9 Date Recue/Date Received 2021-06-30 the present invention, measured by a ligand binding assay and an electrophysiology experiment, respectively.
Figure 11 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, SDS, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MIT stained on the artificial skin tissue using isopropanol.
Figure 12 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, acetic acid, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MIT stained on the artificial corneal tissue using isopropanol.
Figure 13 is a graph illustrating the ALT
(aminotransferase) activity, a liver damage index, measured after the administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
Figure 14 is a graph illustrating the TBARS
(thiobarbituric acid reactive substance) activity, an oxidative stress index, measured after the Date Recue/Date Received 2021-06-30 administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Hereinafter, the present invention is described in detail.
The following description is provided to help the understanding of the present invention, and the present invention is not limited to the content of the following description.
In an aspect of the present invention, the present invention provides a compound represented by formula 1 or a pharmaceutically acceptable salt thereof.
[Formula 1]
Z
R2) __________ n X
(In formula 1, Rl is nonsubstituted or substituted phenyl, wherein the substituted phenyl is substituted with one or more substituents selected from the group Date Recue/Date Received 2021-06-30 consisting of hydroxy, cyano, nitro, amino, halogen, and nonsubstituted or substituted straight or branched C1-5 alkyl, wherein the substituted alkyl is substituted with halogen;
R2 is hydroxy, amino, cyano, halogen, C1-3 straight or branched alkyl, or C1-3 straight or branched alkoxy;
n is an integer of 0 - 8;
X and Y are independently CH or N; and Z is sulfinyl or sulfonyl).
In a preferred embodiment of the present invention, Rl can be phenyl substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, and CF3.
In another embodiment of the present invention, Rl is substituted phenyl, the substituted phenyl is substituted with one or more substituents selected from the group consisting of halogen and CF3;
any one of X and Y is CH and the other is N; and Z is S(0).
In another embodiment of the present invention, if any one of X and Y is CH, the other can be N.
Date Recue/Date Received 2021-06-30 In another embodiment of the present invention, if X is CH, Y is N.
In another embodiment of the present invention, the compound represented by formula 1 can be any one compound selected from the following compound group, or a pharmaceutically acceptable salt thereof:
(1) 1-((4-fluorophenyl)sulfinyl)isoquinoline;
(2) 4-((4-fluorophenyl)sulfinyl)quinoline;
(3) 1-((2,4-difluorophenyl)sulfinyl)isoquinoline;
(4) 1-((4-chlorophenyl)sulfinyl)isoquinoline; and (5) 1-((4-(trifluoromethyl)phenyl)sulfinyl)isoquinoline.
The compound represented by formula 1 of the present invention can be used as a form of a pharmaceutically acceptable salt, in which the salt is preferably acid addition salt formed by pharmaceutically acceptable free acids. The acid addition salt herein can be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, and phosphorous acid;
non-toxic organic acids such as aliphatic mono/dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate, alkandioate, aromatic acids, and aliphatic/aromatic sulfonic acids; or organic acids such as acetic acid, benzoic acid, citric acid, lactic Date Recue/Date Received 2021-06-30 acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, and fumaric acid. The pharmaceutically non-toxic salts are exemplified by sulfate, pyrosulfate, bisulfate, sulphite, bisulphite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutylate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, cabacate, fumarate, maliate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutylate, citrate, lactate, P-hydroxybutylate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
The acid addition salt in this invention can be prepared by the conventional method known to those in the art. For example, the derivative represented by formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, dichloromethane, and Date Recue/Date Received 2021-06-30 acetonitrile, to which organic acid or inorganic acid is added to induce precipitation. Then, the precipitate is filtered and dried to give the salt.
Or the solvent and the excessive acid are distillated under reduced pressure, and dried to give the salt.
Or the precipitate is crystallized in an organic solvent to give the same.
In addition, the present invention includes not only the compound represented by formula 1 but also a pharmaceutically acceptable salt thereof, and a solvate, an optical isomer, or a hydrate possibly produced from the same.
In another aspect of the present invention, the present invention provides a preparation method of a compound represented by formula 1 comprising a step of preparing a compound represented by formula 1 from a compound represented by formula 4; as shown in reaction formula 1 below.
[Reaction Formula 1]
CI
(R2) ___________________________ ;
n X n ci;
X
(In reaction formula 1, Date Recue/Date Received 2021-06-30 Rl, R2, n, X, Y and Z are as defined in formula 1 above).
In another embodiment of the present invention, when Z is sulfinyl or sulfonyl, the compound represented by formula 1 can be understood to be a compound represented by Formula 1".
The preparation method can comprises the following steps, as shown in reaction formula 3 below:
preparing a compound represented by formula 1 by reacting a compound represented by formula 4 with a compound represented by formula 3; and preparing a compound represented by formula 1"
from the compound represented by formula 1' prepared in the above step.
[Reaction Formula 3]
R1 .R1 CI S"
\ A y R1 _______________________________________ 'T (R2) R2) +
n HS- n 1.;,-) X n X X
(In reaction formula 3, Rl, R2, n, X and Y are as defined in formula 1 above; and W is sulfinyl or sulfonyl).
In the step of preparing a compound represented by formula 1' by reacting a compound represented by Date Recue/Date Received 2021-06-30 formula 4 with a compound represented by formula 3, the usable solvent is exemplified by H20, ethanol, tetrahydrofuran (THF), dichloromethane, toluene, acetonitrile and dimethylformamide, and ethanol is more preferred herein. In addition, the reaction time is not particularly limited, but it is preferable to react for 5 to 30 hours, 10 to 20 hours, or about 12 hours. Further, the reaction temperature is not particularly limited, but it is preferable to perform at room temperature or 20 to 30r.
In the most preferred embodiment of the present invention, the methods that can be carried out as in the following examples of the present invention, and can be changed such as the aspects and conditions of the experiments are also included in the scope of the present invention.
In addition, in the step of preparing a compound represented by formula 1" from the compound represented by formula 1 prepared in the above step, the above step can be considered a reaction of introducing a sulfinyl group or a sulfonyl group, but not always limited thereto. For example, the reaction can be carried out using m-chloroperoxybenzoic acid or the like. As a solvent, C1-C4 alcohol, acetone, acetonitrile, benzene, 2-butanone, chlorobenzene, Date Recue/Date Received 2021-06-30 chloroform, cyclohexane, toluene, 1,2-dichloromethane (DCM), heptane, hexane, etc. can be used, and chloroform can be preferably used. The reaction time is not particularly limited, but it is preferable to react for 5 to 30 hours, 10 to 20 hours, or about 12 hours. Further, the reaction temperature is not particularly limited, but it is preferable to perform at room temperature or 20 to 30r.
In the most preferred embodiment of the present invention, the methods that can be carried out as in the following examples of the present invention, and can be changed such as the aspects and conditions of the experiments are also included in the scope of the present invention.
In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating autophagy related diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the compound represented by formula 1 or the pharmaceutically acceptable salt thereof can be understood as an active ingredient for regulating autophagy activity.
Date Recue/Date Received 2021-06-30 In a preferred embodiment of the present invention, the autophagy activity was regulated by the compound represented by formula 1 of the present invention as shown in Experimental Example 1.
Particularly, autophagy may be a process mediated by the exposure of cells to stress, such as nutrient supply blockage, bacterial invasion, and the like. The compound represented by formula 1 of the present invention can be understood as an active ingredient that regulates the autophagy activity, exhibits an anti-inflammatory effect capable of suppressing an inflammatory response through inhibition of NO
production and inflammation-related factors such as IL-6 and IL-p, has an effect of inhibiting melanogenesis, has an inhibitory effect on metabolic syndrome such as fatty liver suppression and obesity suppression, and exhibits a significant effect on other autophagy related diseases.
In addition, the compound represented by formula 1 of the present invention has been found to be a safe compound in general cytotoxicity test, cardiotoxicity evaluation, skin toxicity evaluation, ocular toxicity evaluation, and liver damage evaluation, suggesting that it can be provided as an active ingredient of a safer therapeutic agent in the living body.
N
Date Recue/Date Received 2021-06-30 In another embodiment of the present invention, the autophagy related disease includes all the diseases that have been identified, studied, or reported to be related to autophagy activity, and includes, for example, cancer, atherosclerosis, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxia, oculopharyngeal muscular dystrophy, prion disease, fatal familial insomnia, alpha-1 antitrypsin deficiency, dentatorubral pallidoluysian atrophy, frontotemporal dementia, progressive supranuclear palsy, x-linked spinobulbar muscular atrophy and neuronal intranuclear hyaline inclusion disease.
In another embodiment of the present invention, the autophagy related disease can be a metabolic syndrome-related disease (otherwise a metabolic disease), and includes, for example, obesity, diabetes, dyslipidemia, alcoholic fatty liver, non-alcoholic fatty liver, hypertension, arteriosclerosis, hyperlipidemia and hyperinsulinemia, etc.
In another embodiment of the present invention, the autophagy related disease can be an inflammatory disease, and for example, can be a disease that can be improved, prevented, or treated by inhibiting NO
Date Recue/Date Received 2021-06-30 production, IL-6 or IL-1 p expression, and the like.
The inflammatory disease can be, for example, an intestinal disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis, non-alcoholic hepatitis, and the like.
In another embodiment of the present invention, the autophagy related disease can be a disease related to melanogenesis, and can be a skin disease caused by melanin overproduction, for example, skin hyperpigmentation.
Herein, the skin disease caused by melanin overproduction can be understood as a disease including the lesions caused by pigmentation such as melasma, freckles, lentigo and age spots.
In the above-mentioned autophagy diseases, the compound represented by formula 1 of the present invention or a pharmaceutically acceptable salt thereof can exhibit medically useful effects such as prevention, amelioration, and treatment of the diseases. This is supported by the Examples and Experimental Examples of the present specification, and thus, a pharmaceutical composition containing the same as an active ingredient can be provided.
On the other hand, a pharmaceutical composition Date Recue/Date Received 2021-06-30 for preventing or treating the following diseases can be provided purely based on those shown in Experimental Examples of the present invention not limited to the autophagy related diseases, that is regardless of the above-described autophagy-related theories or mechanisms deviating from the effects and explanations related to autophagy described herein.
In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating inflammatory or metabolic diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the inflammatory disease can be a disease that can be improved, prevented, or treated from inhibiting NO production, IL-6 or IL-1 p expression, and the like. The inflammatory disease can be, for example, an intestinal disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis, non-alcoholic hepatitis, and the like.
As shown in the following Experimental Examples and Figures 3, 4 and 5 of the present invention, the compound represented by formula 1 was confirmed to have the effect of inhibiting NO production and IL-6 Date Recue/Date Received 2021-06-30 or IL-1 p expression. This effect can be explained as being related to the autophagy regulation effect or it can be explained as an independent effect, but not always limited thereto. Rather, regardless of this, a pharmaceutical composition for preventing or treating inflammatory diseases can be provided from the inflammatory response inhibitory effect demonstrated herein.
In addition, the metabolic disease can be understood as metabolic syndrome, for example, obesity, diabetes, dyslipidemia, alcoholic fatty liver, non-alcoholic fatty liver, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, etc.
As shown in the following Experimental Examples and Figures 7 and 8 of the present invention, the compound represented by formula 1 was confirmed to have the effect of inhibiting fatty liver. This effect can be explained as being related to the autophagy regulation effect or it can be explained as an independent effect, but not always limited thereto.
Rather, regardless of this, a pharmaceutical composition for preventing or treating metabolic diseases can be provided from the fatty liver and liver damage inhibitory effect demonstrated herein.
Date Recue/Date Received 2021-06-30 In addition, in another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating skin hyperpigmentation containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the skin hyperpigmentation can be, for example, a skin disease caused by melanin overproduction, and can be a disease including the lesions caused by pigmentation such as melasma, freckles, lentigo, and senile pigmentation spots.
As shown in the following Experimental Examples and Figures 6A to 6C of the present invention, the compound represented by formula 1 of the present invention was confirmed to excellently inhibit melanogenesis at all time points before and after the formation of melanocytes. Therefore, a pharmaceutical composition for preventing or treating skin hyperpigmentation containing the same as an active ingredient can be provided.
The compound represented by formula 1 can be administered in various oral and parenteral formulations during clinical administration. In the case of formulation, it can be prepared using generally used diluents or excipients such as fillers, Date Recue/Date Received 2021-06-30 extenders, binders, wetting agents, disintegrating agents and surfactants.
Solid formulations for oral administration are exemplified by tablets, pills, granules, capsules, and troches, etc. These solid formulations are prepared by mixing one or more compounds of the present invention with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc.
Except for the simple excipients, lubricants, for example magnesium stearate, talc, etc, can be used.
Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, flavoring agents and preservatives in addition to generally used simple diluents such as water and liquid paraffin.
Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, emulsions, lyophilized preparations and suppositories.
Water insoluble excipients and suspensions can contain propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc. Suppositories can contain witepsol, Date Recue/Date Received 2021-06-30 macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, etc.
In addition, the compound of the present invention can be formulated as creams, ointments, gels, lotions, solutions, or transdermal preparations such as patches.
The effective dosage of the compound of the present invention to the human body can be determined according to age, may vary depending on the patient's age, weight, gender, administration method, health condition, and severity of disease, and is generally about 0.001 - 100 mg/kg/day, and preferably 0.01 - 35 mg/kg/day. The dosage is generally 0.07 - 7000 mg/day, and preferably 0.7 - 2500 mg/day based on an adult patient weighing 70 kg, which can be administered once or several times a day at intervals of a certain time depending on the judgment of a doctor or a pharmacist.
In another aspect of the present invention, the present invention provides a method for treating autophagy related diseases comprising a step of administering a compound represented by formula 1 or a pharmaceutically acceptable salt thereof to a subject in a therapeutically effective amount.
At this time, the autophagy related disease is as described herein.
Date Recue/Date Received 2021-06-30 The therapeutically effective amount refers to an amount capable of treating, preventing, or ameliorating the symptoms or conditions of a subject when administered into the body, depending on the administration method. In addition, the amount may vary depending on the weight, age, gender, condition, and family history of the subject to be administered.
In the treatment method of the present invention, different dosages may be determined according to the different conditions for each subject.
The "effective amount" is an amount effective to treat autophagy related diseases, such as cancer, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxia, oculopharyngeal muscular dystrophy, prion disease, fatal familial insomnia, alpha-1 antitrypsin deficiency, dentatorubral pallidoluysian atrophy, frontotemporal dementia, progressive supranuclear palsy, x-linked spinobulbar muscular atrophy or neuronal intranuclear hyaline inclusion disease. In another embodiment of the present invention, the "effective amount" of a compound means more than the minimum amount capable of regulating autophagy activity.
Date Recue/Date Received 2021-06-30 The compound and composition according to the present invention can be administered using any route of administration in any amount effective to treat a disease. The exact amount required may vary from subject to subject, depending on the subject's species, age, and general condition, the severity of the infection, the particular agent, its mode of administration, and the like. The compound of the present invention is frequently formulated in a dosage unit form for ease of administration and uniformity of dosage. The "dosage unit form" as used herein refers to a physically discrete unit of an agent suitable for the subject to be treated. It will also be understood that the total daily dosage of the compound and composition of the present invention can be determined by an attending physician within the scope of a sound medical judgment. The particular effective dosage level for any particular subject or organism depends on the following a variety of factors: the disease to be treated and the severity of the disease; activity of the particular compound used; the particular composition used; age, weight, general health, gender and diet of the subject; administration time, administration route, and excretion rate of the particular compound used; duration of treatment; the Date Recue/Date Received 2021-06-30 particular compound used alone or co-administered drugs, and other factors than those well known in the medical art.
The term "subject" refers to a subject for whom the compound, the pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided in the present invention is desired. Alternatively, the subject means a subject in need of the effect of prevention, amelioration, or treatment of autophagy related diseases. For example, the subject can be an animal, preferably a non-mammal or a mammal, more preferably a livestock or a human, and most preferably a human.
In another aspect, the present invention provides a health functional food composition or a cosmetic composition as follows.
In an aspect of the present invention, the present invention provides a health functional food composition for preventing or ameliorating autophagy related diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the autophagy related disease includes all the diseases that have been identified, studied, or reported to be related to autophagy activity, and Date Recue/Date Received 2021-06-30 includes, for example, cancer, atherosclerosis, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxia, oculopharyngeal muscular dystrophy, prion disease, fatal familial insomnia, alpha-1 antitrypsin deficiency, dentatorubral pallidoluysian atrophy, frontotemporal dementia, progressive supranuclear palsy, x-linked spinobulbar muscular atrophy and neuronal intranuclear hyaline inclusion disease.
In another aspect of the present invention, the present invention provides a health functional food composition for preventing or ameliorating inflammatory or metabolic diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the inflammatory disease can be a disease that can be improved, prevented, or treated from inhibiting NO production, IL-6 or IL-1 expression, and the like. For example, the inflammatory disease can be an intestinal disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis, non-alcoholic hepatitis, and the like.
Date Recue/Date Received 2021-06-30 In addition, the metabolic disease can be understood as metabolic syndrome, for example, obesity, diabetes, dyslipidemia, alcoholic fatty liver, non-alcoholic fatty liver, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, etc.
Further, in another aspect of the present invention, the present invention provides a cosmetic composition for whitening containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the cosmetic composition can inhibit melanogenesis by containing the compound represented by formula 1 as an active ingredient. Therefore, the cosmetic composition can be effectively used as a cosmetic composition for whitening, when used for the purpose of inhibiting melanin formation in the skin, hair, and particularly in the eye.
The compound represented by formula 1, a component of the cosmetic composition for whitening, was confirmed to be a toxicologically safe component to the living body such as cells, skin, and eyes, as shown in Experimental Examples of the present invention. Therefore, the compound of the present invention can be applied without any special Date Recue/Date Received 2021-06-30 restrictions on the site to be applied in order to inhibit the formation of melanocytes and the melanin synthesis.
In a preferred embodiment of the present invention, as shown in the following Experimental Examples and Figure 6, the compound represented by formula 1 of the present invention significantly inhibited the formation of melanocytes, and inhibited the melanin synthesis of the already generated melanocytes. Therefore, the cosmetic composition can be provided as a cosmetic composition for whitening.
In particularly, the composition can be effectively used for a subject suffering from skin hyperpigmentation, for example, can be usefully used for the lesions caused by pigmentation such as melasma, freckles, lentigo, and senile pigmentation spots.
Alternatively, the composition can be effectively used for the purpose of skin whitening, even if the subject is not suffering from the disease.
On the other hand, the formulation of the cosmetic composition of the present invention is not particularly limited and can be arbitrarily selected and applied. The composition can be prepared and used in various formulations like the conventional cosmetic Date Recue/Date Received 2021-06-30 formulations such as external skin ointment, essence, whitening cream, lotion, emulsion, pack, general lotion, skin milk, cream, serum, beauty soap, softening lotion, medicinal lotion, hair tonic, body cleanser, and oil gel, etc.
Hereinafter, the present invention will be described in detail by the following examples and experimental examples.
However, the following examples and experimental examples are only for illustrating the present invention, and the contents of the present invention are not limited thereto.
<Example 1> Preparation of fluorophenyl)sulfinyl)isoquinoline IN
Step 1: Preparation of 1-((4-fluorophenyl)thio)isoquinoline 4-Fluorobenzenethiol (1.436 mL, 13.447 mmol) was added to ethanol containing 1-chloroisoquinoline (2 g, 12.225 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel Date Recue/Date Received 2021-06-30 column chromatography using ethyl acetate/hexane to give a target compound (686 mg, 22%).
IH NMR (400MHz, DMSO-d6) 5 8.28 (d, J = 8.24 Hz, 1H), 8.18 (d, J = 5.49 Hz, 1H), 7.99 (d, J = 8.24 Hz, 1H), 7.81-7.85 (m, 1H), 7.72-7.77 (m, 1H), 7.61-7.66 (m, 3H), 7.29-7.35 (m, 2H).
Step 2: Preparation of 1-((4-fluorophenyl)sulfinyl)isoquinoline The 1-((4-fluorophenyl)thio)isoquinoline (850 mg, 3.329 mmol) prepared in step 1 was dissolved in THF/water. Oxone (574.53 mg, 3.329 mmol) was added to the mixture, followed by stirring at room temperature for 12 hours. The mixture was diluted with water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target pure compound (218 mg. 24%).
IH NMR (400MHz, CDC13) 5 8.79 (d, J = 8.54 Hz, 1H), 8.47 (d, J = 5.49 Hz, 1H), 7.52-7.76 (m, 6H), 6.99 (t, J = 8.54 Hz, 2H).
<Example 2> Preparation of 4-((4-fluorophenyl)sulfinyl)quinoline Date Recue/Date Received 2021-06-30 ./(TF
11( Step 1: Preparation of 4-((4-fluorophenyl)thio)quinolone The experiment was performed as described in step 1 of Example 1, except that 4-chloroquinoline (250 mg, 1.528 mmol) was used instead of 1-chloroisoquinoline.
4-Fluorobenzenethiol (250 mg, 1.528 mmol) was added to ethanol containing 4-chloroquinoline (250 mg, 1.528 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target compound (185.0 mg, 47.4%).
1FINMR (400 MHz, CDC13) 6 8.565 (d, J = 4.88 Hz, 1H), 8.178 (d, J = 9.16 Hz, 1H), 8.069 (d, J = 8.24 Hz, 1H), 7.730 (m, 1H), 7.583 (m, 3H), 7.181 (t, J =
17.40, 2H), 6.673 (d, J = 4.58, 1H).
Step 2: Preparation of 4-((4-fluorophenyl)sulfinyl)quinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 4-((4-fluorophenyl)thio)quinolone (280 Date Recue/Date Received 2021-06-30 mg, 1.097 mmol) prepared in step 1 was used instead of 1-((4-fluorophenyl)thio)isoquinoline.
1FINMR (400 MHz, CDC13) 5 9.124 (d, J = 4.58 Hz, 1H), 8.156 (m, 2H), 7.974 (d, J = 8.85 Hz, 1H), 7.711 (m, 3H), 7.572 (m, 1H), 7.096 (t, J = 17.09 Hz, 2H).
<Example 3> Preparation of difluorophenyl)sulfinyl)isoquinoline a F,,.,........ F
I
ON. ' NN, Step 1: Preparation of 1-((2,4-difluorophenyl)thio)isoquinoline The experiment was performed as described in step 1 of Example 1, except that 2,4-difluorobenzenethiol (1.527 mmol) was used instead of 4-fluorobenzenethiol.
2,4-Difluorobenzenethiol (1.527 mmol) was added to ethanol containing 1-chloroquinoline (0.25 g, 1.527 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo.
The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target compound (42%).
1FINMR (400 MHz, CDC13) 5 8.308 (d, J = 8.24 Hz, 1H), 8.159 (d, J = 5.95 Hz, 1H), 7.778 (d, J = 8.24 Date Recue/Date Received 2021-06-30 Hz, 1H), 7.690 (t, J = 14.95 Hz, 1H), 7.602 (m, 2H), 7.367 (d, J = 5.49 Hz, 1H), 6.961 (m, 2H).
Step 2: Preparation of 1-((2,4-difluorophenyl)sulfinyl)isoquinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 1-((2,4-difluorophenyl)thio)isoquinoline (200 mg) prepared in step 1 was used (57%).
1FINMR (400 MHz, CDC13) 6 8.685 (d, J = 8.24 Hz, 1H), 8.579 (d, J = 5.49 Hz, 1H), 8.085 (m, 1H), 7.898 (d, J = 8.24 Hz, 1H), 7.742 (m, 3H), 7.074 (m, 1H), 6.747 (m, 1H).
<Example 4> Preparation of chlorophenyl)sulfinyl)isoquinoline 0: I
Step 1: Preparation of 1-((4-chlorophenyl)thio)isoquinoline A target compound was prepared by the similar manner to the method described in step 1 of Example 1, except that 4-chlorobenzenethiol (1.527 mmol) was used instead of 4-fluorobenzenethiol (48%).
Date Recue/Date Received 2021-06-30 11-INMR (400 MHz, CDC13) 5 8.313 (d, J = 8.24, 1H), 8.220 (d, J = 5.80 Hz, 1H), 7.782 (d, J = 8.24 Hz, 1H), 7.690 (m, 1H), 7.607 (m, 1H), 7.510 (m, 2H), 7.379 (m, 3H).
Step 2: Preparation of 1-((4-chlorophenyl)sulfinyl)isoquinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 1-((4-chlorophenyl)thio)isoquinoline (200 mg) prepared in step 1 was used (25%).
iHNMR (400 MHz, CDC13) 5 8.903 (d, J = 8.54Hz, 1H), 8.558 (d, J = 5.49 Hz, 1H), 7.871 (d, J = 8.24 Hz, 1H), 7.750 (m, 3H), 7.706 (d, J = 5.49 Hz, 1H), 7.648 (m, 1H), 7.374 (d, J = 8.54 Hz, 2H).
<Example 5> Preparation of (trifluoromethyl)phenyl)sulfinyl)isoquinoline cj,õCFs S' ..N
Step 1: Preparation of 1-((4-(trifluoromethyl)phenyl)thio)isoquinoline A target compound was prepared by the similar manner to the method described in step 1 of Example 1, Date Recue/Date Received 2021-06-30 except that 4-(trifluoromethyl)benzenethiol (1.527 mmol) was used instead of 4-fluorobenzenethiol (59%).
11-INMR (400 MHz, CDC13) 6 8.335 (d, J = 8.24 Hz, 1H), 8.269 (d, J = 5.49 Hz, 1H), 7.811 (d, J = 7.93 Hz, 1H), 7.710 (m, 1H), 7.630 (m, 5H), 7.465 (d, J =
5.49 Hz, 1H).
Step 2: Preparation of 1-((4-(trifluoromethyl)phenyl)sulfinyl)isoquinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 1-((4-(trifluoromethyl)phenyl)thio)isoquinoline (250 mg) was used prepared in step 1 (62%).
11-INMR (400 MHz, CDC13) 6 8.972 (d, J = 8.54 Hz, 1H), 8.558 (d, J = 5.49 Hz, 1H), 7.946 (d, J = 8.24 Hz, 2H), 7.880 (d, J = 8.24 Hz, 1H), 7.714 (m, 5H).
Structural formulas of the compounds prepared in Examples 1 - 7 are shown in Table 1 below.
<Comparative Example 1> Preparation of 1-((4-fluorophenyl)thio)isoquinoline S -Step 1: Preparation of 1-((4-Date Recue/Date Received 2021-06-30 fluorophenyl)thio)isoquinoline 4-Fluorobenzenethiol (1.436 mL, 13.447 mmol) was added to ethanol containing 1-chloroisoquinoline (2 g, 12.225 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target compound (686 mg, 22%).
11-1 NMR (400MHz, DMSO-d6) 5 8.28 (d, J = 8.24 Hz, 1H), 8.18 (d, J = 5.49 Hz, 1H), 7.99 (d, J = 8.24 Hz, 1H), 7.81-7.85 (m, 1H), 7.72-7.77 (m, 1H), 7.61-7.66 (m, 3H), 7.29-7.35 (m, 2H).
<Comparative Example 2> Preparation of 1-((4-fluorophenyl)sulfonyl)isoquinoline 40yF
0, j."0 rrµ-' Step 1: Preparation of 1-((4-fluorophenyl)thio)isoquinoline 4-Fluorobenzenethiol (1.436 mL, 13.447 mmol) was added to ethanol containing 1-chloroisoquinoline (2 g, 12.225 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel Date Recue/Date Received 2021-06-30 column chromatography using ethyl acetate/hexane to give a target compound (686 mg, 22%).
IH NMR (400MHz, DMSO-d6) 5 8.28 (d, J = 8.24 Hz, 1H), 8.18 (d, J = 5.49 Hz, 1H), 7.99 (d, J = 8.24 Hz, 1H), 7.81-7.85 (m, 1H), 7.72-7.77 (m, 1H), 7.61-7.66 (m, 3H), 7.29-7.35 (m, 2H).
Step 2: Preparation of 1-((4-fluorophenyl)sulfonyl)isoquinoline 1-((4-Fluorophenyl)thio)isoquinoline (850 mg, 3.329 mmol) was dissolved in THF/water. Oxone (2.2 eq, 7.3238 mmol) was added to the mixture, followed by stirring at room temperature for 12 hours. The mixture was diluted with water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target pure compound (4 c, 66%).
IHNMR (400 MHz, CDC13) 5 8.79 (d, J = 8.54 Hz, 1H), 8.47 (d, J = 5.49 Hz, 1H), 7.52-7.76 (m, 6H), 6.99 (t, J = 8.54 Hz, 2H).
<Experimental Example 1> Evaluation of autophagy regulatory activity In order to evaluate the autophagy regulating activity of the novel isoquinoline derivative Date Recue/Date Received 2021-06-30 according to the present invention, the following experiment was performed.
<1-1> Analysis of autophagy indices The conversion from LC3-I to LC3-II, which is an autophagy index, was analyzed by Western blotting.
Particularly, for Western blotting, RAW264.7 cells, which are mouse macrophages, were aliquoted into 60 mm cell culture dishes at the density of 20 x 105 cells/dish and cultured for one day. The cells were treated with the compound of Example 1 of the present invention using DMSO at the concentrations of 1, 5, 10 and 20 pM, followed by culture in a 37r, CO2 incubator for one day. After detaching the cells using 0.1% trypsin-EDTA, the cells were collected by centrifugation. The cells were lysed using a lysis buffer (RIPA lysis buffer) (50 mM Tris, pH 7.4, 0.1%
SDS, 1% NP-40, 150 mM NaCl, 1mM PMSF, 10 mM NaF, 10 ug/ml aprotinin, 10 ug/ml leupeptin, 10 mM Na3VO4) and then centrifuged to obtain a cell lysate. The obtained cell lysate was quantified for protein, and a cell lysate containing the same amount (50 ug) of protein was separated by electrophoresis on a 4-12% Bis-Tris acrylamide gel. Proteins in the obtained cell lysate were quantified, and the cell lysate containing the same amount (50 ug) of protein was separated by Date Recue/Date Received 2021-06-30 electrophoresis on a 4-12% Bis-Tris acrylamide gel.
After the isolated proteins were transferred to a PVDF
membrane, Western blotting was performed. Blocking of the PVDF membrane was performed in TBST (25 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-200) containing 5%
skim milk for 1 hour. An anti-LC3 antibody was used as the primary antibody. As an internal standard protein, anti-GAPDH purchased from Santacruz was used. The primary antibody was reacted at room temperature for 3 hours. The membrane was washed three times with TBST
buffer, and reacted with a secondary antibody (horseradish peroxidase-conjugated anti-goat IgG) at room temperature for 2 hours. Upon completion of the reaction, the PVDF membrane was washed three times with TBST buffer, reacted with ECL solution, and chemiluminescence was obtained using an imaging device. The results confirmed by Western blotting are shown in Figure 1.
Figure 1 is a set of Western blot diagrams confirming the conversions of LC3-I and LC3-II
according to the treatment of the compound of Example 1 of the present invention at the concentrations of 1, 5, 10, and 20 pM in Raw 264.7 mouse macrophages.
<1-2> Intracellular autophagosome visualization analysis Date Recue/Date Received 2021-06-30 In order to detect autophagosomes formed by regulation of autophagy, analysis of observation was performed using acridine orange, which selectively stains acidic vesicles in the cytoplasm.
Particularly, the fluorescence characteristics of autophagosomes are changed by protonation of acridine orange accumulated due to acidification in the cytoplasm. An experiment was performed as follows using these fluorescence characteristics.
Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 5 x 104 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours.
The Raw 264.7 cells were treated with the compound of Example 1 at the concentrations of 5, 10, 20 and 50 pM. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. After removing the medium and replacing it with a medium containing 5 pM
acridine orange, the cells were stained in a 37r, 5%
CO2 incubator for 15 minutes. After staining was completed, the cells were washed with PBS, and the formation of intracellular autophagosomes was observed under a fluorescence microscope. The results visualized by acridine orange fluorescence are shown in Figure 2.
Figure 2 is a set of fluorescence micrographs Date Recue/Date Received 2021-06-30 confirming the changes in autophagosomes observed after the treatment of the compound of Example 1 of the present invention at the concentrations of 5, 10, 20, and 50 pM in Raw 264.7 mouse macrophages in which inflammatory response was induced by treatment of LPS.
<Experimental Example 2> Evaluation of disease-related drug efficacy <2-1> Measurement of anti-inflammatory (NO) activity Macrophages are cells that cause inflammatory responses. These cells play a biodefense role by producing NO and cytokines when stress or stimulation occurs. NO plays an essential role in the innate immune response in response to pathogens such as viruses and bacteria, and L-arginine is produced by NO
synthase (NOS). NOS is divided into cNOS (constitutive NOS) and iNOS (inducible NOS). Among them, iNOS
induces inflammatory responses by generating a large amount of NO by stimulation such as stress or cytokines.
In order to confirm the effect of the compound of Example 1 of the present invention on NO production in Raw 264.7 mouse macrophages in which inflammatory response was induced by LPS, an experiment was performed as follows.
Date Recue/Date Received 2021-06-30 Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 1 x 105 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours.
The Raw 264.7 cells were treated with the compound of Example 1 by concentration. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. For the measurement of NO production, 40 mg/ml of Griess reagent was prepared and it was mixed with the culture supernatant at the same ratio. The mixture was reacted at room temperature for 15 minutes, and absorbance was measured at 540 nm. Based on the results obtained therefrom, the cell viability and NO
production rate were expressed as percentages in terms of LPS. The results are shown in Table 2 below.
Meanwhile, the results for the compound of Example 1 are presented in Figure 3.
[Table 1]
Cell viability NO production (% of control) (% of control) Example 1 90 40 Example 2 100 26 Example 3 103 30 Example 4 96 40 Example 5 101 25 Comparative Example 1 95 70 Comparative Example 2 73 65 In Figure 3, the upper graph shows the NO
production rate measured by absorbance using Griess reagent as percentages compared to LPS after Date Recue/Date Received 2021-06-30 regulating NO production by LPS (regulating inflammatory response), and treating the compound of Example 1 of the present invention with 0.1, 0.5, 1,
Figure 11 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, SDS, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MIT stained on the artificial skin tissue using isopropanol.
Figure 12 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, acetic acid, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MIT stained on the artificial corneal tissue using isopropanol.
Figure 13 is a graph illustrating the ALT
(aminotransferase) activity, a liver damage index, measured after the administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
Figure 14 is a graph illustrating the TBARS
(thiobarbituric acid reactive substance) activity, an oxidative stress index, measured after the Date Recue/Date Received 2021-06-30 administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Hereinafter, the present invention is described in detail.
The following description is provided to help the understanding of the present invention, and the present invention is not limited to the content of the following description.
In an aspect of the present invention, the present invention provides a compound represented by formula 1 or a pharmaceutically acceptable salt thereof.
[Formula 1]
Z
R2) __________ n X
(In formula 1, Rl is nonsubstituted or substituted phenyl, wherein the substituted phenyl is substituted with one or more substituents selected from the group Date Recue/Date Received 2021-06-30 consisting of hydroxy, cyano, nitro, amino, halogen, and nonsubstituted or substituted straight or branched C1-5 alkyl, wherein the substituted alkyl is substituted with halogen;
R2 is hydroxy, amino, cyano, halogen, C1-3 straight or branched alkyl, or C1-3 straight or branched alkoxy;
n is an integer of 0 - 8;
X and Y are independently CH or N; and Z is sulfinyl or sulfonyl).
In a preferred embodiment of the present invention, Rl can be phenyl substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, and CF3.
In another embodiment of the present invention, Rl is substituted phenyl, the substituted phenyl is substituted with one or more substituents selected from the group consisting of halogen and CF3;
any one of X and Y is CH and the other is N; and Z is S(0).
In another embodiment of the present invention, if any one of X and Y is CH, the other can be N.
Date Recue/Date Received 2021-06-30 In another embodiment of the present invention, if X is CH, Y is N.
In another embodiment of the present invention, the compound represented by formula 1 can be any one compound selected from the following compound group, or a pharmaceutically acceptable salt thereof:
(1) 1-((4-fluorophenyl)sulfinyl)isoquinoline;
(2) 4-((4-fluorophenyl)sulfinyl)quinoline;
(3) 1-((2,4-difluorophenyl)sulfinyl)isoquinoline;
(4) 1-((4-chlorophenyl)sulfinyl)isoquinoline; and (5) 1-((4-(trifluoromethyl)phenyl)sulfinyl)isoquinoline.
The compound represented by formula 1 of the present invention can be used as a form of a pharmaceutically acceptable salt, in which the salt is preferably acid addition salt formed by pharmaceutically acceptable free acids. The acid addition salt herein can be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, and phosphorous acid;
non-toxic organic acids such as aliphatic mono/dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate, alkandioate, aromatic acids, and aliphatic/aromatic sulfonic acids; or organic acids such as acetic acid, benzoic acid, citric acid, lactic Date Recue/Date Received 2021-06-30 acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, and fumaric acid. The pharmaceutically non-toxic salts are exemplified by sulfate, pyrosulfate, bisulfate, sulphite, bisulphite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutylate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, cabacate, fumarate, maliate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutylate, citrate, lactate, P-hydroxybutylate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
The acid addition salt in this invention can be prepared by the conventional method known to those in the art. For example, the derivative represented by formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, dichloromethane, and Date Recue/Date Received 2021-06-30 acetonitrile, to which organic acid or inorganic acid is added to induce precipitation. Then, the precipitate is filtered and dried to give the salt.
Or the solvent and the excessive acid are distillated under reduced pressure, and dried to give the salt.
Or the precipitate is crystallized in an organic solvent to give the same.
In addition, the present invention includes not only the compound represented by formula 1 but also a pharmaceutically acceptable salt thereof, and a solvate, an optical isomer, or a hydrate possibly produced from the same.
In another aspect of the present invention, the present invention provides a preparation method of a compound represented by formula 1 comprising a step of preparing a compound represented by formula 1 from a compound represented by formula 4; as shown in reaction formula 1 below.
[Reaction Formula 1]
CI
(R2) ___________________________ ;
n X n ci;
X
(In reaction formula 1, Date Recue/Date Received 2021-06-30 Rl, R2, n, X, Y and Z are as defined in formula 1 above).
In another embodiment of the present invention, when Z is sulfinyl or sulfonyl, the compound represented by formula 1 can be understood to be a compound represented by Formula 1".
The preparation method can comprises the following steps, as shown in reaction formula 3 below:
preparing a compound represented by formula 1 by reacting a compound represented by formula 4 with a compound represented by formula 3; and preparing a compound represented by formula 1"
from the compound represented by formula 1' prepared in the above step.
[Reaction Formula 3]
R1 .R1 CI S"
\ A y R1 _______________________________________ 'T (R2) R2) +
n HS- n 1.;,-) X n X X
(In reaction formula 3, Rl, R2, n, X and Y are as defined in formula 1 above; and W is sulfinyl or sulfonyl).
In the step of preparing a compound represented by formula 1' by reacting a compound represented by Date Recue/Date Received 2021-06-30 formula 4 with a compound represented by formula 3, the usable solvent is exemplified by H20, ethanol, tetrahydrofuran (THF), dichloromethane, toluene, acetonitrile and dimethylformamide, and ethanol is more preferred herein. In addition, the reaction time is not particularly limited, but it is preferable to react for 5 to 30 hours, 10 to 20 hours, or about 12 hours. Further, the reaction temperature is not particularly limited, but it is preferable to perform at room temperature or 20 to 30r.
In the most preferred embodiment of the present invention, the methods that can be carried out as in the following examples of the present invention, and can be changed such as the aspects and conditions of the experiments are also included in the scope of the present invention.
In addition, in the step of preparing a compound represented by formula 1" from the compound represented by formula 1 prepared in the above step, the above step can be considered a reaction of introducing a sulfinyl group or a sulfonyl group, but not always limited thereto. For example, the reaction can be carried out using m-chloroperoxybenzoic acid or the like. As a solvent, C1-C4 alcohol, acetone, acetonitrile, benzene, 2-butanone, chlorobenzene, Date Recue/Date Received 2021-06-30 chloroform, cyclohexane, toluene, 1,2-dichloromethane (DCM), heptane, hexane, etc. can be used, and chloroform can be preferably used. The reaction time is not particularly limited, but it is preferable to react for 5 to 30 hours, 10 to 20 hours, or about 12 hours. Further, the reaction temperature is not particularly limited, but it is preferable to perform at room temperature or 20 to 30r.
In the most preferred embodiment of the present invention, the methods that can be carried out as in the following examples of the present invention, and can be changed such as the aspects and conditions of the experiments are also included in the scope of the present invention.
In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating autophagy related diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the compound represented by formula 1 or the pharmaceutically acceptable salt thereof can be understood as an active ingredient for regulating autophagy activity.
Date Recue/Date Received 2021-06-30 In a preferred embodiment of the present invention, the autophagy activity was regulated by the compound represented by formula 1 of the present invention as shown in Experimental Example 1.
Particularly, autophagy may be a process mediated by the exposure of cells to stress, such as nutrient supply blockage, bacterial invasion, and the like. The compound represented by formula 1 of the present invention can be understood as an active ingredient that regulates the autophagy activity, exhibits an anti-inflammatory effect capable of suppressing an inflammatory response through inhibition of NO
production and inflammation-related factors such as IL-6 and IL-p, has an effect of inhibiting melanogenesis, has an inhibitory effect on metabolic syndrome such as fatty liver suppression and obesity suppression, and exhibits a significant effect on other autophagy related diseases.
In addition, the compound represented by formula 1 of the present invention has been found to be a safe compound in general cytotoxicity test, cardiotoxicity evaluation, skin toxicity evaluation, ocular toxicity evaluation, and liver damage evaluation, suggesting that it can be provided as an active ingredient of a safer therapeutic agent in the living body.
N
Date Recue/Date Received 2021-06-30 In another embodiment of the present invention, the autophagy related disease includes all the diseases that have been identified, studied, or reported to be related to autophagy activity, and includes, for example, cancer, atherosclerosis, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxia, oculopharyngeal muscular dystrophy, prion disease, fatal familial insomnia, alpha-1 antitrypsin deficiency, dentatorubral pallidoluysian atrophy, frontotemporal dementia, progressive supranuclear palsy, x-linked spinobulbar muscular atrophy and neuronal intranuclear hyaline inclusion disease.
In another embodiment of the present invention, the autophagy related disease can be a metabolic syndrome-related disease (otherwise a metabolic disease), and includes, for example, obesity, diabetes, dyslipidemia, alcoholic fatty liver, non-alcoholic fatty liver, hypertension, arteriosclerosis, hyperlipidemia and hyperinsulinemia, etc.
In another embodiment of the present invention, the autophagy related disease can be an inflammatory disease, and for example, can be a disease that can be improved, prevented, or treated by inhibiting NO
Date Recue/Date Received 2021-06-30 production, IL-6 or IL-1 p expression, and the like.
The inflammatory disease can be, for example, an intestinal disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis, non-alcoholic hepatitis, and the like.
In another embodiment of the present invention, the autophagy related disease can be a disease related to melanogenesis, and can be a skin disease caused by melanin overproduction, for example, skin hyperpigmentation.
Herein, the skin disease caused by melanin overproduction can be understood as a disease including the lesions caused by pigmentation such as melasma, freckles, lentigo and age spots.
In the above-mentioned autophagy diseases, the compound represented by formula 1 of the present invention or a pharmaceutically acceptable salt thereof can exhibit medically useful effects such as prevention, amelioration, and treatment of the diseases. This is supported by the Examples and Experimental Examples of the present specification, and thus, a pharmaceutical composition containing the same as an active ingredient can be provided.
On the other hand, a pharmaceutical composition Date Recue/Date Received 2021-06-30 for preventing or treating the following diseases can be provided purely based on those shown in Experimental Examples of the present invention not limited to the autophagy related diseases, that is regardless of the above-described autophagy-related theories or mechanisms deviating from the effects and explanations related to autophagy described herein.
In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating inflammatory or metabolic diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the inflammatory disease can be a disease that can be improved, prevented, or treated from inhibiting NO production, IL-6 or IL-1 p expression, and the like. The inflammatory disease can be, for example, an intestinal disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis, non-alcoholic hepatitis, and the like.
As shown in the following Experimental Examples and Figures 3, 4 and 5 of the present invention, the compound represented by formula 1 was confirmed to have the effect of inhibiting NO production and IL-6 Date Recue/Date Received 2021-06-30 or IL-1 p expression. This effect can be explained as being related to the autophagy regulation effect or it can be explained as an independent effect, but not always limited thereto. Rather, regardless of this, a pharmaceutical composition for preventing or treating inflammatory diseases can be provided from the inflammatory response inhibitory effect demonstrated herein.
In addition, the metabolic disease can be understood as metabolic syndrome, for example, obesity, diabetes, dyslipidemia, alcoholic fatty liver, non-alcoholic fatty liver, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, etc.
As shown in the following Experimental Examples and Figures 7 and 8 of the present invention, the compound represented by formula 1 was confirmed to have the effect of inhibiting fatty liver. This effect can be explained as being related to the autophagy regulation effect or it can be explained as an independent effect, but not always limited thereto.
Rather, regardless of this, a pharmaceutical composition for preventing or treating metabolic diseases can be provided from the fatty liver and liver damage inhibitory effect demonstrated herein.
Date Recue/Date Received 2021-06-30 In addition, in another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating skin hyperpigmentation containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the skin hyperpigmentation can be, for example, a skin disease caused by melanin overproduction, and can be a disease including the lesions caused by pigmentation such as melasma, freckles, lentigo, and senile pigmentation spots.
As shown in the following Experimental Examples and Figures 6A to 6C of the present invention, the compound represented by formula 1 of the present invention was confirmed to excellently inhibit melanogenesis at all time points before and after the formation of melanocytes. Therefore, a pharmaceutical composition for preventing or treating skin hyperpigmentation containing the same as an active ingredient can be provided.
The compound represented by formula 1 can be administered in various oral and parenteral formulations during clinical administration. In the case of formulation, it can be prepared using generally used diluents or excipients such as fillers, Date Recue/Date Received 2021-06-30 extenders, binders, wetting agents, disintegrating agents and surfactants.
Solid formulations for oral administration are exemplified by tablets, pills, granules, capsules, and troches, etc. These solid formulations are prepared by mixing one or more compounds of the present invention with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc.
Except for the simple excipients, lubricants, for example magnesium stearate, talc, etc, can be used.
Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, flavoring agents and preservatives in addition to generally used simple diluents such as water and liquid paraffin.
Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, emulsions, lyophilized preparations and suppositories.
Water insoluble excipients and suspensions can contain propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc. Suppositories can contain witepsol, Date Recue/Date Received 2021-06-30 macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, etc.
In addition, the compound of the present invention can be formulated as creams, ointments, gels, lotions, solutions, or transdermal preparations such as patches.
The effective dosage of the compound of the present invention to the human body can be determined according to age, may vary depending on the patient's age, weight, gender, administration method, health condition, and severity of disease, and is generally about 0.001 - 100 mg/kg/day, and preferably 0.01 - 35 mg/kg/day. The dosage is generally 0.07 - 7000 mg/day, and preferably 0.7 - 2500 mg/day based on an adult patient weighing 70 kg, which can be administered once or several times a day at intervals of a certain time depending on the judgment of a doctor or a pharmacist.
In another aspect of the present invention, the present invention provides a method for treating autophagy related diseases comprising a step of administering a compound represented by formula 1 or a pharmaceutically acceptable salt thereof to a subject in a therapeutically effective amount.
At this time, the autophagy related disease is as described herein.
Date Recue/Date Received 2021-06-30 The therapeutically effective amount refers to an amount capable of treating, preventing, or ameliorating the symptoms or conditions of a subject when administered into the body, depending on the administration method. In addition, the amount may vary depending on the weight, age, gender, condition, and family history of the subject to be administered.
In the treatment method of the present invention, different dosages may be determined according to the different conditions for each subject.
The "effective amount" is an amount effective to treat autophagy related diseases, such as cancer, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxia, oculopharyngeal muscular dystrophy, prion disease, fatal familial insomnia, alpha-1 antitrypsin deficiency, dentatorubral pallidoluysian atrophy, frontotemporal dementia, progressive supranuclear palsy, x-linked spinobulbar muscular atrophy or neuronal intranuclear hyaline inclusion disease. In another embodiment of the present invention, the "effective amount" of a compound means more than the minimum amount capable of regulating autophagy activity.
Date Recue/Date Received 2021-06-30 The compound and composition according to the present invention can be administered using any route of administration in any amount effective to treat a disease. The exact amount required may vary from subject to subject, depending on the subject's species, age, and general condition, the severity of the infection, the particular agent, its mode of administration, and the like. The compound of the present invention is frequently formulated in a dosage unit form for ease of administration and uniformity of dosage. The "dosage unit form" as used herein refers to a physically discrete unit of an agent suitable for the subject to be treated. It will also be understood that the total daily dosage of the compound and composition of the present invention can be determined by an attending physician within the scope of a sound medical judgment. The particular effective dosage level for any particular subject or organism depends on the following a variety of factors: the disease to be treated and the severity of the disease; activity of the particular compound used; the particular composition used; age, weight, general health, gender and diet of the subject; administration time, administration route, and excretion rate of the particular compound used; duration of treatment; the Date Recue/Date Received 2021-06-30 particular compound used alone or co-administered drugs, and other factors than those well known in the medical art.
The term "subject" refers to a subject for whom the compound, the pharmaceutically acceptable salt thereof, or the pharmaceutical composition provided in the present invention is desired. Alternatively, the subject means a subject in need of the effect of prevention, amelioration, or treatment of autophagy related diseases. For example, the subject can be an animal, preferably a non-mammal or a mammal, more preferably a livestock or a human, and most preferably a human.
In another aspect, the present invention provides a health functional food composition or a cosmetic composition as follows.
In an aspect of the present invention, the present invention provides a health functional food composition for preventing or ameliorating autophagy related diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the autophagy related disease includes all the diseases that have been identified, studied, or reported to be related to autophagy activity, and Date Recue/Date Received 2021-06-30 includes, for example, cancer, atherosclerosis, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, spinocerebellar ataxia, oculopharyngeal muscular dystrophy, prion disease, fatal familial insomnia, alpha-1 antitrypsin deficiency, dentatorubral pallidoluysian atrophy, frontotemporal dementia, progressive supranuclear palsy, x-linked spinobulbar muscular atrophy and neuronal intranuclear hyaline inclusion disease.
In another aspect of the present invention, the present invention provides a health functional food composition for preventing or ameliorating inflammatory or metabolic diseases containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the inflammatory disease can be a disease that can be improved, prevented, or treated from inhibiting NO production, IL-6 or IL-1 expression, and the like. For example, the inflammatory disease can be an intestinal disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis, non-alcoholic hepatitis, and the like.
Date Recue/Date Received 2021-06-30 In addition, the metabolic disease can be understood as metabolic syndrome, for example, obesity, diabetes, dyslipidemia, alcoholic fatty liver, non-alcoholic fatty liver, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, etc.
Further, in another aspect of the present invention, the present invention provides a cosmetic composition for whitening containing a compound represented by formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Herein, the cosmetic composition can inhibit melanogenesis by containing the compound represented by formula 1 as an active ingredient. Therefore, the cosmetic composition can be effectively used as a cosmetic composition for whitening, when used for the purpose of inhibiting melanin formation in the skin, hair, and particularly in the eye.
The compound represented by formula 1, a component of the cosmetic composition for whitening, was confirmed to be a toxicologically safe component to the living body such as cells, skin, and eyes, as shown in Experimental Examples of the present invention. Therefore, the compound of the present invention can be applied without any special Date Recue/Date Received 2021-06-30 restrictions on the site to be applied in order to inhibit the formation of melanocytes and the melanin synthesis.
In a preferred embodiment of the present invention, as shown in the following Experimental Examples and Figure 6, the compound represented by formula 1 of the present invention significantly inhibited the formation of melanocytes, and inhibited the melanin synthesis of the already generated melanocytes. Therefore, the cosmetic composition can be provided as a cosmetic composition for whitening.
In particularly, the composition can be effectively used for a subject suffering from skin hyperpigmentation, for example, can be usefully used for the lesions caused by pigmentation such as melasma, freckles, lentigo, and senile pigmentation spots.
Alternatively, the composition can be effectively used for the purpose of skin whitening, even if the subject is not suffering from the disease.
On the other hand, the formulation of the cosmetic composition of the present invention is not particularly limited and can be arbitrarily selected and applied. The composition can be prepared and used in various formulations like the conventional cosmetic Date Recue/Date Received 2021-06-30 formulations such as external skin ointment, essence, whitening cream, lotion, emulsion, pack, general lotion, skin milk, cream, serum, beauty soap, softening lotion, medicinal lotion, hair tonic, body cleanser, and oil gel, etc.
Hereinafter, the present invention will be described in detail by the following examples and experimental examples.
However, the following examples and experimental examples are only for illustrating the present invention, and the contents of the present invention are not limited thereto.
<Example 1> Preparation of fluorophenyl)sulfinyl)isoquinoline IN
Step 1: Preparation of 1-((4-fluorophenyl)thio)isoquinoline 4-Fluorobenzenethiol (1.436 mL, 13.447 mmol) was added to ethanol containing 1-chloroisoquinoline (2 g, 12.225 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel Date Recue/Date Received 2021-06-30 column chromatography using ethyl acetate/hexane to give a target compound (686 mg, 22%).
IH NMR (400MHz, DMSO-d6) 5 8.28 (d, J = 8.24 Hz, 1H), 8.18 (d, J = 5.49 Hz, 1H), 7.99 (d, J = 8.24 Hz, 1H), 7.81-7.85 (m, 1H), 7.72-7.77 (m, 1H), 7.61-7.66 (m, 3H), 7.29-7.35 (m, 2H).
Step 2: Preparation of 1-((4-fluorophenyl)sulfinyl)isoquinoline The 1-((4-fluorophenyl)thio)isoquinoline (850 mg, 3.329 mmol) prepared in step 1 was dissolved in THF/water. Oxone (574.53 mg, 3.329 mmol) was added to the mixture, followed by stirring at room temperature for 12 hours. The mixture was diluted with water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target pure compound (218 mg. 24%).
IH NMR (400MHz, CDC13) 5 8.79 (d, J = 8.54 Hz, 1H), 8.47 (d, J = 5.49 Hz, 1H), 7.52-7.76 (m, 6H), 6.99 (t, J = 8.54 Hz, 2H).
<Example 2> Preparation of 4-((4-fluorophenyl)sulfinyl)quinoline Date Recue/Date Received 2021-06-30 ./(TF
11( Step 1: Preparation of 4-((4-fluorophenyl)thio)quinolone The experiment was performed as described in step 1 of Example 1, except that 4-chloroquinoline (250 mg, 1.528 mmol) was used instead of 1-chloroisoquinoline.
4-Fluorobenzenethiol (250 mg, 1.528 mmol) was added to ethanol containing 4-chloroquinoline (250 mg, 1.528 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target compound (185.0 mg, 47.4%).
1FINMR (400 MHz, CDC13) 6 8.565 (d, J = 4.88 Hz, 1H), 8.178 (d, J = 9.16 Hz, 1H), 8.069 (d, J = 8.24 Hz, 1H), 7.730 (m, 1H), 7.583 (m, 3H), 7.181 (t, J =
17.40, 2H), 6.673 (d, J = 4.58, 1H).
Step 2: Preparation of 4-((4-fluorophenyl)sulfinyl)quinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 4-((4-fluorophenyl)thio)quinolone (280 Date Recue/Date Received 2021-06-30 mg, 1.097 mmol) prepared in step 1 was used instead of 1-((4-fluorophenyl)thio)isoquinoline.
1FINMR (400 MHz, CDC13) 5 9.124 (d, J = 4.58 Hz, 1H), 8.156 (m, 2H), 7.974 (d, J = 8.85 Hz, 1H), 7.711 (m, 3H), 7.572 (m, 1H), 7.096 (t, J = 17.09 Hz, 2H).
<Example 3> Preparation of difluorophenyl)sulfinyl)isoquinoline a F,,.,........ F
I
ON. ' NN, Step 1: Preparation of 1-((2,4-difluorophenyl)thio)isoquinoline The experiment was performed as described in step 1 of Example 1, except that 2,4-difluorobenzenethiol (1.527 mmol) was used instead of 4-fluorobenzenethiol.
2,4-Difluorobenzenethiol (1.527 mmol) was added to ethanol containing 1-chloroquinoline (0.25 g, 1.527 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo.
The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target compound (42%).
1FINMR (400 MHz, CDC13) 5 8.308 (d, J = 8.24 Hz, 1H), 8.159 (d, J = 5.95 Hz, 1H), 7.778 (d, J = 8.24 Date Recue/Date Received 2021-06-30 Hz, 1H), 7.690 (t, J = 14.95 Hz, 1H), 7.602 (m, 2H), 7.367 (d, J = 5.49 Hz, 1H), 6.961 (m, 2H).
Step 2: Preparation of 1-((2,4-difluorophenyl)sulfinyl)isoquinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 1-((2,4-difluorophenyl)thio)isoquinoline (200 mg) prepared in step 1 was used (57%).
1FINMR (400 MHz, CDC13) 6 8.685 (d, J = 8.24 Hz, 1H), 8.579 (d, J = 5.49 Hz, 1H), 8.085 (m, 1H), 7.898 (d, J = 8.24 Hz, 1H), 7.742 (m, 3H), 7.074 (m, 1H), 6.747 (m, 1H).
<Example 4> Preparation of chlorophenyl)sulfinyl)isoquinoline 0: I
Step 1: Preparation of 1-((4-chlorophenyl)thio)isoquinoline A target compound was prepared by the similar manner to the method described in step 1 of Example 1, except that 4-chlorobenzenethiol (1.527 mmol) was used instead of 4-fluorobenzenethiol (48%).
Date Recue/Date Received 2021-06-30 11-INMR (400 MHz, CDC13) 5 8.313 (d, J = 8.24, 1H), 8.220 (d, J = 5.80 Hz, 1H), 7.782 (d, J = 8.24 Hz, 1H), 7.690 (m, 1H), 7.607 (m, 1H), 7.510 (m, 2H), 7.379 (m, 3H).
Step 2: Preparation of 1-((4-chlorophenyl)sulfinyl)isoquinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 1-((4-chlorophenyl)thio)isoquinoline (200 mg) prepared in step 1 was used (25%).
iHNMR (400 MHz, CDC13) 5 8.903 (d, J = 8.54Hz, 1H), 8.558 (d, J = 5.49 Hz, 1H), 7.871 (d, J = 8.24 Hz, 1H), 7.750 (m, 3H), 7.706 (d, J = 5.49 Hz, 1H), 7.648 (m, 1H), 7.374 (d, J = 8.54 Hz, 2H).
<Example 5> Preparation of (trifluoromethyl)phenyl)sulfinyl)isoquinoline cj,õCFs S' ..N
Step 1: Preparation of 1-((4-(trifluoromethyl)phenyl)thio)isoquinoline A target compound was prepared by the similar manner to the method described in step 1 of Example 1, Date Recue/Date Received 2021-06-30 except that 4-(trifluoromethyl)benzenethiol (1.527 mmol) was used instead of 4-fluorobenzenethiol (59%).
11-INMR (400 MHz, CDC13) 6 8.335 (d, J = 8.24 Hz, 1H), 8.269 (d, J = 5.49 Hz, 1H), 7.811 (d, J = 7.93 Hz, 1H), 7.710 (m, 1H), 7.630 (m, 5H), 7.465 (d, J =
5.49 Hz, 1H).
Step 2: Preparation of 1-((4-(trifluoromethyl)phenyl)sulfinyl)isoquinoline A target compound was prepared by the similar manner to the method described in step 2 of Example 1, except that the 1-((4-(trifluoromethyl)phenyl)thio)isoquinoline (250 mg) was used prepared in step 1 (62%).
11-INMR (400 MHz, CDC13) 6 8.972 (d, J = 8.54 Hz, 1H), 8.558 (d, J = 5.49 Hz, 1H), 7.946 (d, J = 8.24 Hz, 2H), 7.880 (d, J = 8.24 Hz, 1H), 7.714 (m, 5H).
Structural formulas of the compounds prepared in Examples 1 - 7 are shown in Table 1 below.
<Comparative Example 1> Preparation of 1-((4-fluorophenyl)thio)isoquinoline S -Step 1: Preparation of 1-((4-Date Recue/Date Received 2021-06-30 fluorophenyl)thio)isoquinoline 4-Fluorobenzenethiol (1.436 mL, 13.447 mmol) was added to ethanol containing 1-chloroisoquinoline (2 g, 12.225 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target compound (686 mg, 22%).
11-1 NMR (400MHz, DMSO-d6) 5 8.28 (d, J = 8.24 Hz, 1H), 8.18 (d, J = 5.49 Hz, 1H), 7.99 (d, J = 8.24 Hz, 1H), 7.81-7.85 (m, 1H), 7.72-7.77 (m, 1H), 7.61-7.66 (m, 3H), 7.29-7.35 (m, 2H).
<Comparative Example 2> Preparation of 1-((4-fluorophenyl)sulfonyl)isoquinoline 40yF
0, j."0 rrµ-' Step 1: Preparation of 1-((4-fluorophenyl)thio)isoquinoline 4-Fluorobenzenethiol (1.436 mL, 13.447 mmol) was added to ethanol containing 1-chloroisoquinoline (2 g, 12.225 mmol). The reactant was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel Date Recue/Date Received 2021-06-30 column chromatography using ethyl acetate/hexane to give a target compound (686 mg, 22%).
IH NMR (400MHz, DMSO-d6) 5 8.28 (d, J = 8.24 Hz, 1H), 8.18 (d, J = 5.49 Hz, 1H), 7.99 (d, J = 8.24 Hz, 1H), 7.81-7.85 (m, 1H), 7.72-7.77 (m, 1H), 7.61-7.66 (m, 3H), 7.29-7.35 (m, 2H).
Step 2: Preparation of 1-((4-fluorophenyl)sulfonyl)isoquinoline 1-((4-Fluorophenyl)thio)isoquinoline (850 mg, 3.329 mmol) was dissolved in THF/water. Oxone (2.2 eq, 7.3238 mmol) was added to the mixture, followed by stirring at room temperature for 12 hours. The mixture was diluted with water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane to give a target pure compound (4 c, 66%).
IHNMR (400 MHz, CDC13) 5 8.79 (d, J = 8.54 Hz, 1H), 8.47 (d, J = 5.49 Hz, 1H), 7.52-7.76 (m, 6H), 6.99 (t, J = 8.54 Hz, 2H).
<Experimental Example 1> Evaluation of autophagy regulatory activity In order to evaluate the autophagy regulating activity of the novel isoquinoline derivative Date Recue/Date Received 2021-06-30 according to the present invention, the following experiment was performed.
<1-1> Analysis of autophagy indices The conversion from LC3-I to LC3-II, which is an autophagy index, was analyzed by Western blotting.
Particularly, for Western blotting, RAW264.7 cells, which are mouse macrophages, were aliquoted into 60 mm cell culture dishes at the density of 20 x 105 cells/dish and cultured for one day. The cells were treated with the compound of Example 1 of the present invention using DMSO at the concentrations of 1, 5, 10 and 20 pM, followed by culture in a 37r, CO2 incubator for one day. After detaching the cells using 0.1% trypsin-EDTA, the cells were collected by centrifugation. The cells were lysed using a lysis buffer (RIPA lysis buffer) (50 mM Tris, pH 7.4, 0.1%
SDS, 1% NP-40, 150 mM NaCl, 1mM PMSF, 10 mM NaF, 10 ug/ml aprotinin, 10 ug/ml leupeptin, 10 mM Na3VO4) and then centrifuged to obtain a cell lysate. The obtained cell lysate was quantified for protein, and a cell lysate containing the same amount (50 ug) of protein was separated by electrophoresis on a 4-12% Bis-Tris acrylamide gel. Proteins in the obtained cell lysate were quantified, and the cell lysate containing the same amount (50 ug) of protein was separated by Date Recue/Date Received 2021-06-30 electrophoresis on a 4-12% Bis-Tris acrylamide gel.
After the isolated proteins were transferred to a PVDF
membrane, Western blotting was performed. Blocking of the PVDF membrane was performed in TBST (25 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-200) containing 5%
skim milk for 1 hour. An anti-LC3 antibody was used as the primary antibody. As an internal standard protein, anti-GAPDH purchased from Santacruz was used. The primary antibody was reacted at room temperature for 3 hours. The membrane was washed three times with TBST
buffer, and reacted with a secondary antibody (horseradish peroxidase-conjugated anti-goat IgG) at room temperature for 2 hours. Upon completion of the reaction, the PVDF membrane was washed three times with TBST buffer, reacted with ECL solution, and chemiluminescence was obtained using an imaging device. The results confirmed by Western blotting are shown in Figure 1.
Figure 1 is a set of Western blot diagrams confirming the conversions of LC3-I and LC3-II
according to the treatment of the compound of Example 1 of the present invention at the concentrations of 1, 5, 10, and 20 pM in Raw 264.7 mouse macrophages.
<1-2> Intracellular autophagosome visualization analysis Date Recue/Date Received 2021-06-30 In order to detect autophagosomes formed by regulation of autophagy, analysis of observation was performed using acridine orange, which selectively stains acidic vesicles in the cytoplasm.
Particularly, the fluorescence characteristics of autophagosomes are changed by protonation of acridine orange accumulated due to acidification in the cytoplasm. An experiment was performed as follows using these fluorescence characteristics.
Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 5 x 104 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours.
The Raw 264.7 cells were treated with the compound of Example 1 at the concentrations of 5, 10, 20 and 50 pM. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. After removing the medium and replacing it with a medium containing 5 pM
acridine orange, the cells were stained in a 37r, 5%
CO2 incubator for 15 minutes. After staining was completed, the cells were washed with PBS, and the formation of intracellular autophagosomes was observed under a fluorescence microscope. The results visualized by acridine orange fluorescence are shown in Figure 2.
Figure 2 is a set of fluorescence micrographs Date Recue/Date Received 2021-06-30 confirming the changes in autophagosomes observed after the treatment of the compound of Example 1 of the present invention at the concentrations of 5, 10, 20, and 50 pM in Raw 264.7 mouse macrophages in which inflammatory response was induced by treatment of LPS.
<Experimental Example 2> Evaluation of disease-related drug efficacy <2-1> Measurement of anti-inflammatory (NO) activity Macrophages are cells that cause inflammatory responses. These cells play a biodefense role by producing NO and cytokines when stress or stimulation occurs. NO plays an essential role in the innate immune response in response to pathogens such as viruses and bacteria, and L-arginine is produced by NO
synthase (NOS). NOS is divided into cNOS (constitutive NOS) and iNOS (inducible NOS). Among them, iNOS
induces inflammatory responses by generating a large amount of NO by stimulation such as stress or cytokines.
In order to confirm the effect of the compound of Example 1 of the present invention on NO production in Raw 264.7 mouse macrophages in which inflammatory response was induced by LPS, an experiment was performed as follows.
Date Recue/Date Received 2021-06-30 Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 1 x 105 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours.
The Raw 264.7 cells were treated with the compound of Example 1 by concentration. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. For the measurement of NO production, 40 mg/ml of Griess reagent was prepared and it was mixed with the culture supernatant at the same ratio. The mixture was reacted at room temperature for 15 minutes, and absorbance was measured at 540 nm. Based on the results obtained therefrom, the cell viability and NO
production rate were expressed as percentages in terms of LPS. The results are shown in Table 2 below.
Meanwhile, the results for the compound of Example 1 are presented in Figure 3.
[Table 1]
Cell viability NO production (% of control) (% of control) Example 1 90 40 Example 2 100 26 Example 3 103 30 Example 4 96 40 Example 5 101 25 Comparative Example 1 95 70 Comparative Example 2 73 65 In Figure 3, the upper graph shows the NO
production rate measured by absorbance using Griess reagent as percentages compared to LPS after Date Recue/Date Received 2021-06-30 regulating NO production by LPS (regulating inflammatory response), and treating the compound of Example 1 of the present invention with 0.1, 0.5, 1,
10, and 100 pM, respectively, and the lower graph shows the cell viability rate according to the treatment of each LPS and the compound of Example 1 of the present invention with 0.1, 0.5, 1, 10, and 100 pM, respectively, as percentages compared to the control.
As shown in Figure 3, it was confirmed that the NO production was inhibited by the treatment of the compound of Example 1 of the present invention, and the inhibitory effect of the NO production was increased as the treatment concentration was increased, but the compound of Example 1 of the present invention showed no significant cytotoxicity.
<2-2> Measurement of inflammatory response-related cytokine gene expression In RAW264.7 macrophages activated by treatment of LPS, the expressions of inflammatory cytokine mRNA and protein are increased. Inflammatory cytokines are known to activate macrophages and mediate acute and chronic inflammatory responses.
Therefore, investigating the inhibition of cytokine mRNA and Date Recue/Date Received 2021-06-30 protein secretion by LPS stimulation is important for the development of anti-inflammatory drugs.
Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 1 x 105 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours.
The Raw 264.7 cells were treated with the compound of Example 1 at the concentration of 1 or 10 pM. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. After removing the medium, the cells were washed with PBS. After detaching the cells using 0.1% trypsin-EDTA, the cells were collected by centrifugation. RNA was isolated from the cell precipitation using Trizole reagent. The amount of the isolated RNA was quantified by measuring absorbance at 260 nm. Real-time polymerase chain reaction was performed using a real-time PCR machine (ABI 7500 fast-real time PCR, Applied Biosystem, USA) by mixing about 100 ng of RNA with Verso SYBR Green 1-Step gRT-PCR Low ROX Mix according to the manufacturer's manual.
The genes used for real-time polymerase chain reaction were obtained from Bioneer. The polymerase reaction was carried out at 50r for 15 minutes and at 95r for 15 minutes, followed by denaturation at 95r for 15 seconds, annealing at 60r for 15 seconds, Date Recue/Date Received 2021-06-30 polymerization at 72r, 40 cycles from denaturation to polymerization. The results are shown in Figure 4.
Figure 4 is a graph illustrating the effect of the compound of Example 1 of the present invention on the expression of the inflammatory response-related cytokine IL-6 gene.
<2-3> Measurement of inflammatory response-related protein expression In order to measure the anti-inflammatory effect of the novel isoquinoline derivative of the present invention, an experiment was performed as follows.
In Raw 264.7 macrophages, the inflammatory proteins interleukin-6 (IL-6) and interleukin-lbeta (IL-1p) were secreted out of the cells due to the regulation of inflammatory response by LPS treatment.
This experiment is a method to evaluate the anti-inflammatory activity by measuring the amount of inflammatory proteins secreted after the regulation of the inflammatory response caused by LPS using an enzyme-linked immunosorbent assay (ELISA).
Particularly, Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 1 x 105 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours. The Raw 264.7 cells were treated with the compound of Example 1 at the concentrations of Date Recue/Date Received 2021-06-30 0.1, 1 and 10 pM. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. After taking only the cell culture medium, centrifugation was performed at 13,000 rpm for 5 minutes to take only the supernatant. The secreted Interleukin was quantified using a commercially available kit from Elabscience according to the manufacturer's manual.
According to the method, the cell culture solution was dispensed into the provided wells (100 pl/well), and then incubated at 37r for 90 minutes. The culture medium was removed and 100 pl of a biotin-conjugated selective antibody was reacted at 37r for 1 hour, and then washed three times with a washing solution.
Thereafter, 100 pl of a solution labeled with horseradish peroxidase (HRP) was reacted at 37r for 30 minutes, and then washed 5 times with a washing solution. After adding 90 pl of a solution containing a HRP-specific substrate, incubated at 37r for 15 minutes. The reaction was terminated by adding 90 pl of a termination solution, and the absorbance was measured at 450 nm. The experimental results are shown in Figure 5.
Figure 5 is a set of graphs illustrating the effect of the compound of Example 1 of the present invention at the concentrations of 0.1, 1, and 10 pM
Date Recue/Date Received 2021-06-30 on the secretion of the inflammatory response-related proteins IL-6 and IL-1p.
<2-4> Evaluation of whitening effect In order to evaluate the whitening effect of the novel isoquinoline derivative of the present invention, an experiment was performed as follows.
Black melanocytes of zebrafish do not migrate to keratinocytes, but rather exist in melanocytes. When observing the regeneration of melanin pigment, after inhibiting the formation of melanin pigment, it can be investigated by limiting it to the melanocyte generation pathway, and it is easy to observe the melanin synthesized in the initial stage of development. Therefore, zebrafish is more useful for the study of melanin pigment changes compared to other animal models (Logan DW, Burn SF, Jackson IJ. (2006) Regulation of pigmentation in zebrafish melanophores.
Pigment Cell Res. 2006 Jun; 19(3):206-13.).
Particularly, zebrafish fertilized eggs 10 hours after fertilization were placed in a 24-well plate (10 eggs/well), and 1 ml of egg water was added to each well of the plate. The compound of Example 1 was added to each well at the concentrations of 0.1 pM and 1 pM, so that the final volume of each well was 2 ml. Then, each 24-well plate was wrapped in foil to block light, Date Recue/Date Received 2021-06-30 and then incubated in a 28r incubator for 22 hours.
At 32 hours after fertilization, in order to photograph the formation of black melanocytes, the chorion of the developing embryo was peeled off using a forcep (Fine Science Tools). After anesthetizing the developing embryo with Tricaine (4 g/L), the embryo was photographed on 3% methyl cellulose. As the equipment for photographing the developing embryo, a LEICA MZ1OF fluorescence microscope, a LEICA DFC425 camera, and Leica Application Suite software (v4.5) were used. In all the experimental procedures, egg water sterilized after dissolving 60 mg/L of sea salt (Sigma-Aldrich, S9883) in tertiary distilled water was used as a solution for culturing the developing embryo. As a control group, a solvent control group (0.4% DMSO) and phenylthiourea (200 pM PTU), known as a tyrosinase inhibitor, were used (Figure 6A).
In the same manner, experiments were performed with the compound of Comparative Example 1 at the concentrations of 0.5 pM, 1 pM, and 5 pM, and the results are shown in Figure 6B.
On the other hand, in order to confirm the ability of the compound of the present invention to inhibit the melanin synthesis of the already generated melanocytes, the following experiment was performed Date Recue/Date Received 2021-06-30 with juvenile fish 60 hours after fertilization.
Particularly, juvenile fish 60 hours after fertilization were placed in a 24-well plate (10/well), and 1 ml of egg water was added to each well of the plate. The compound of Example 1 was added to each well at the concentrations of 10 pM and 20 pM, so that the final volume of each well was 2 ml. Then, each 24-well plate was wrapped in foil to block light, and then incubated in a 28r incubator for 12 hours.
In order to photograph the formation of black melanocytes, the developing embryo was anesthetized with Tricaine (4 g/L), and then the embryo was photographed on 3% methyl cellulose. The above-mentioned equipment was used for photographing (Figure 6C).
The excellent melanin synthesis inhibitory effect of the novel isoquinoline derivative of the present invention was confirmed. In particular, at 32 hours after fertilization, the synthesis of melanin was inhibited in the group treated with the compound of Example 1 of the present invention at the concentration of 1 pM at a level similar to that in the group treated with PTU. This means that the compound of Example 1 has a 5-fold or more superior activity, compared to the compound of Comparative Date Recue/Date Received 2021-06-30 Example 1 that inhibited the synthesis of melanin at a level similar to that of the PTU-treated group when treated with 5 pM. In addition, at 72 hours after fertilization, compared to the group treated with PTU
at the concentration of 0.2 mM, the compound of Example 1 of the present invention was confirmed to have a superior melanin synthesis inhibitory effect compared to PTU, especially when treated with 20 pM.
<2-5> Evaluation of fatty liver inhibitory effect In order to evaluate the inhibitory efficacy of the novel isoquinoline derivative of the present invention on fatty liver, an experiment was performed as follows using LipidGreen2 staining reagent capable of staining lipid droplets.
The proportion of fat in the normal liver is about 5%, and if more fat is accumulated than this, it is called fatty liver. Fatty liver is largely divided into alcoholic fatty liver caused by excessive drinking and non-alcoholic fatty liver caused by obesity, diabetes, hyperlipidemia, drugs, and the like. The main causes of fatty liver are drinking and obesity. Diseases such as hyperlipidemia with a high blood lipid concentration or diabetes may appear together with fatty liver. Drugs such as Date Recue/Date Received 2021-06-30 corticosteroids (steroids) or female hormones can also cause fatty liver.
Tamoxifen is a nonsteroidal anti-estrogen agent that binds to estrogen receptor a/P by competing with estrogen. It was developed by ICI (UK) and has been used the most as an endocrine therapy for female hormone-dependent cancer since the 1980s. In particular, it is known that hepatocyte necrosis occurs in the zebrafish juvenile fish treated with tamoxifen, and steatosis is known to appear in the adult liver.
Particularly, the zebrafish used in this Experimental Example were juvenile fish 5 days after fertilization. Healthy juvenile fish were placed in a 24-well plate (10/well), and 1 ml of egg water was added to each well of the plate. As a negative control that could not regulate fatty liver, DMSO diluted at 0.4% was exposed to juvenile fish, and tamoxifen (Sigma-Aldrich, 15648) diluted at 5 pM was exposed to juvenile fish to control alcoholic fatty liver. In order to investigate the fatty liver inhibitory efficacy of the compound of Example 1 of the present invention, the compound (0.5 pM, 1 pM and 5 pM) was mixed with 5 pM tamoxifen and exposed to juvenile fish (final volume of each well: 2 ml). The 24-well plate Date Recue/Date Received 2021-06-30 containing the compound was wrapped in foil to block light, and then incubated in a 28r incubator for 22 hours. The plate was washed with egg water 3 times for minutes to remove the compound from each well. For 5 fat-specific staining, LipidGreen2 diluted at 5 pM was exposed to juvenile fish for 30 minutes, and then washed 3 times with egg water for 5 minutes. To evaluate the fatty liver of zebrafish juvenile fish, the developing embryo was anesthetized with Tricaine (4 g/L), and then photographed on 3% methyl cellulose.
As the equipment for photographing the developing embryo, a LEICA MZ1OF fluorescence microscope, a LEICA
DFC425 camera, and Leica Application Suite software (v4.5) were used. For the fluorescence wavelength, a GFP Plants filter set (Excitation 470/40 nm, Emission 525/50 nm) was used. To quantify the liver area and the degree of fat staining of juvenile fish on the image, the area and the fluorescence intensity of the liver part of each image were quantified using ImageJ
1.50i software (National Institutes of Health, USA) and converted into heatmap images. The experimental results are shown in Figures 7 and 8.
Figure 7 is a set of general microscope images, fluorescence microscope images and heatmap conversion images observed after the treatment of DMSO, tamoxifen Date Recue/Date Received 2021-06-30 and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization.
Figure 8 is a set of graphs illustrating the results of quantification of liver area (top) and fluorescence intensity (bottom) on the zebrafish juvenile fish images observed after the treatment of DMSO, tamoxifen and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization using ImageJ 1.50i softwear (National Institutes of Health, USA) (The p values are the t-test results for each experimental group compared to the tamoxifen-treated group. *p 0.01, **p 0.001).
In Figure 7, the white dotted lines on the general microscope image and the fluorescence microscope image and the black dotted line on the heatmap conversion image indicate the liver part of the same juvenile fish. In particular, in the heatmap conversion image, a red color indicates the strong fluorescence intensity, and a blue color indicates the weak fluorescence intensity.
As shown in Figure 7, as a result of LipidGreen2 fat staining, it was confirmed that the fatty liver regulated by tamoxifen was restored to the normal Date Recue/Date Received 2021-06-30 level in the group treated with the compound of Example 1 of the present invention.
In Figure 8, the upper part is a graph statistically confirming that the liver area of the juvenile fish of the group treated with the compound of Example 1 of the present invention or tamoxifen was maintained at the liver area level of normal juvenile fish, and the lower part is a graph confirming that the fluorescence intensity of the juvenile fish of the group treated with the compound of Example 1 of the present invention was decreased to the normal level compared to the fluorescence intensity of the juvenile fish of the group treated with tamoxifen. From the above results, it was confirmed that the compound of Example 1 can be effectively used for the treatment or amelioration of fatty liver.
<Experimental Example 3> Toxicity test <3-1> Non-selective general cytotoxicity test In order to evaluate the non-selective cytotoxicity of the compound of Example 1 of the present invention in various cell lines, the following experiment was performed.
In this experiment, the cell lines derived from different species, VERO (African green monkey kidney cell line), HFL-1 (human embryonic lung cell line), Date Recue/Date Received 2021-06-30 L929 (mouse fibroblast cell line), NIH 313 (mouse embryonic fibroblast cell line), CHO-K1 (Chinese hamster ovary cell line) and HMV-II (human malignant melanoma cell line), were used.
Particularly, VERO, HFL-1, L929 and NIH 313 cell lines were cultured in DMEM, CHO-K1 was cultured in RPMI1640 medium, and HMV-II was cultured in DME/F-12 medium. 10% FBS (Fetal Bovine Serum) and 100 pg/mL of antibiotics were added to each medium. The cells were acclimatized and cultured in a humidified 37r 5% CO
incubator, washed with PBS (phosphate buffer solution) at the time of growth that occupies 70-80% of the culture dish every 2-3 days, and then subcultured by treating with Trypsin-EDTA (Gibco, USA).
The cells used in this Experimental Example were aliquoted into a 96-well culture plate at the density of 15,000 - 25,000 cells/well, and then acclimatized and cultured in a humidified 37r 5% CO2 incubator for 24 hours. The compound of Example 1 of the present invention was prepared to be 10 mM using DMSO, and diluted sequentially. Each cell line was treated with the compound at the final concentration, and cultured for 24 hours. The cell viability was measured according to the standard method using a Cyto XTM cell viability assay kit (LPS solution). 10 pl of a Date Recue/Date Received 2021-06-30 chromogenic reagent was added to each well and incubated for 2 hours in a humidified 37r 5% CO2 incubator, followed by measuring the absorbance at 450 nm. The survival rate was measured by calculating the ratio of the absorbance changed compared to the absorbance measured in the group treated with DMSO
alone. The results are shown in Figure 9.
Figure 9 is a graph illustrating the cell viability of VERO, HFL-1, L929, NIH 3T3, CHO-K1 and HMV-II cell lines according to the concentration of the compound of Example 1 of the present invention treated.
As shown in Figure 9, the compound of Example 1 of the present invention had no significant toxicity in all cell lines up to 10 pM, and showed less than 50% cytotoxicity at the maximum test concentration of 100 pM.
<3-2> Cardiotoxicity test In order to evaluate the possibility of inducing cardiotoxicity of the compound of Example 1 of the present invention in vivo, the inhibitory potential to the hERG (human ether-a-go-go related gene) IC+ channel protein, known as a main cause of arrhythmias, was tested.
First, a ligand binding test was performed to Date Recue/Date Received 2021-06-30 evaluate the binding force of the compound of Example 1 binding to the hERG channel protein in vitro. A
biological membrane containing the hERG channel protein was aliquoted in a 384-black well plate (10 p1/well) at room temperature, and DMSO, E-4031 (positive control), and the compound of Example 1 prepared to be 4 times the final test concentration were added thereto (5 pl/well). A tracer material with a fluorescent material attached to astemizole, known as a selective binding substance to the hERG channel protein, was dispensed into a mixture of the two solutions (5 pl/well), and then incubated for 2 hours at room temperature where light was blocked. In order to excite the tracer material included in the reaction solution, the light of 530 nm was irradiated and the light of 585 nm returned back was measured by the polarization method. In this experiment, the high polarization value by the tracer material means a lot of binding between the hERG protein and the tracer.
Conversely, the low polarization value indicates a lot of binding between the hERG protein and the test material. The binding force of the test material to the hERG protein was expressed as the inhibition rate (%) compared to the group treated with DMSO.
Next, in order to evaluate the activity of the Date Recue/Date Received 2021-06-30 hERG channel protein using an electrophysiological method, a patch clamp test was performed. The activity of the hERG channel protein was measured using the HEK-293 cell line overexpressing the hERG channel protein. The cells were acclimatized and cultured in a humidified 37r 5% CO2 incubator, washed with PBS
(phosphate buffer solution) at the time of growth that occupies 70-80% of the culture dish every 2-3 days, and then subcultured by treating with Trypsin-EDTA.
For the test, 2 x 105 cells were aliquoted in a 60 mm cell culture dish, and then cultured in a humidified 5% CO2 incubator for 48 hours. The cultured cells were detached by treating Trypsin-EDTA (Gibco, USA), and the flow of K+ by the hERG channel protein was measured by applying an automated patch clamp equipment (PatchXpress, Molecular Device).
The experimental results of the two experiments above are shown in Figure 10.
Figure 10 is a graph illustrating the inhibition of the binding and activity of the hERG channel protein by the compound of Example 1 of the present invention, presented by ligand binding and patch clamp curves, respectively.
As shown in Figure 10, the inhibition of the binding and activity of the hERG channel protein by Date Recue/Date Received 2021-06-30 the compound of Example 1 of the present invention was found to be about 10% at 10 pM. These results are significantly less than the 50% inhibition rate at 10 pM, which is a standard for judging general toxicity, and thus, it is determined that the compound of Example 1 of the present invention has a low possibility of inducing cardiotoxicity by inhibiting the hERG channel protein in vivo.
<3-3> Skin toxicity test In order to evaluate the skin toxicity that may be induced upon skin contact of the compound of Example 1 of the present invention, the following experiment was performed using the artificial skin prepared with a structure similar to the skin of a living body.
Particularly, the experiment was performed according to OECD Guideline for the Testing of Chemicals No. 439, OECD (2010) and the method recommended by the manufacturer (Tegoscience).
First, the artificial skin cultured in agarose medium was transferred to a 12-well cell culture plate, to which culture medium was added, followed by culture in a humidified 37 C 5% CO2 incubator for one day. The medium on the artificial skin culture surface was eliminated, and 90 pl of the compound of Example 1 Date Recue/Date Received 2021-06-30 of the present invention diluted with PBS was evenly applied to the skin surface, followed by incubation at room temperature for 15 minutes. The cell surface was washed twice with 10 ml of PBS, and a fresh culture medium was added, followed by incubation in a humidified 37r 5% CO2 incubator for 42 hours. In order to measure the viability of the skin, the artificial skin was transferred to a 12-well plate containing 2 ml of MTT solution (0.3 mg/ml), followed by culture for 3 hours. The stained artificial skin tissue was taken and transferred to a tube containing 500 pl of 0.04 N-isopropanol, and then incubated with shaking for 4 hours to decolorize. The solution was centrifuged at 13,000 rpm for 5 minutes, 100 pl of the supernatant was transferred to each well of a 96-well plate, and absorbance was measured at 570 nm. The results are shown in Figure 11.
Figure 11 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, SDS, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MTT stained on the artificial skin tissue using isopropanol.
As shown in Figure 11, a significant decrease of the MTT color development due to necrosis of the skin Date Recue/Date Received 2021-06-30 tissue was observed in the control group treated with 5% SDS, whereas in the group treated with the compound of Example 1 of the present invention, there was no significant decrease of the survival rate up to 20 pM, and a slight decrease of the survival rate was confirmed only in the group treated with the compound at the concentration of 50 pM, the maximum concentration.
<3-4> Ocular toxicity test In order to evaluate the ocular toxicity that may be induced upon ocular exposure of the compound of Example 1 of the present invention, the following experiment was performed using the cultured artificial cornea.
The artificial corneal tissue cultured in agarose medium was transferred to a 12-well cell culture plate, to which culture medium was added, followed by culture in a humidified 37r 5% CO2 incubator for one day. The medium on the artificial cornea culture surface was eliminated, and 30 pl of the compound of Example 1 of the present invention diluted with PBS
was evenly applied to the cornea surface, followed by incubation at room temperature for 30 minutes. The cell surface was washed twice with 10 ml of PBS, and a fresh culture medium was added, followed by incubation Date Recue/Date Received 2021-06-30 in a humidified 37 C 5% CO2 incubator for 30 minutes.
In order to measure the viability of the cornea, the artificial cornea was transferred to a 12-well plate containing 2 ml of MTT solution (1 mg/ml), followed by culture for 3 hours. The stained artificial corneal tissue was taken and transferred to a tube containing 1.5 ml of isopropanol, and then incubated with shaking to decolorize. The solution was centrifuged at 13,000 rpm for 5 minutes, 100 pl of the supernatant was transferred to each well of a 96-well plate, and absorbance was measured at 570 nm. The results are shown in Figure 12.
Figure 12 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, acetic acid, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MTT stained on the artificial corneal tissue using isopropanol.
As shown in Figure 12, a significant decrease of the MTT color development due to necrosis of the corneal tissue was observed in the control group treated with 10% acetic acid, whereas in the group treated with the compound of Example 1 of the present invention, there was no significant decrease of the survival rate up to 50 pM, the maximum concentration.
Date Recue/Date Received 2021-06-30 <3-5> Evaluation of ALT (aminotransferase) activity, a liver damage index In order to evaluate the effect of the compound of Example 1 of the present invention on the activity of a liver damage index, the activity of ALT
(aminotransferase), a liver damage index, was analyzed in ob/ob mice, an obesity-controlled rodent model.
ALT is alanine aminotransferase, which is an enzyme that helps amino acid exchange between keto acids and amino acids. When the enzyme leaked into the blood during cell damage is measured, the enzyme is elevated in liver damage such as viral hepatitis.
Particularly, ob/ob mice (leptin deficient C57B/6 mice) were used as experimental animals, and 10 mpk or 100 mpk of the compound of Example 1 of the present invention was administered for 3 weeks. After administration of the compound, the animals were stunned with CO2 gas and the livers were collected.
After washing the liver tissues with saline, 50 mg was taken and homogenized. Only the lysate was collected separately by centrifugation. The lysate and the substrate for enzyme reaction were added thereto, and the fluorescence value was measured at 535/587 nm. The results are shown in the graph of Figure 13.
Figure 13 is a graph illustrating the ALT
Date Recue/Date Received 2021-06-30 (aminotransferase) activity, a liver damage index, measured after the administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
<3-6> Evaluation of oxidative stress In order to evaluate the oxidative stress of the compound of Example 1 of the present invention, the activity of TBARS (Thiobarbituric acid reactive substance), an oxidative stress index, was analyzed in ob/ob mice, an obesity-controlled rodent model.
Lipid peroxidation is a well-known mechanism of cell damage and is used as an index of oxidative stress. Measurement of TBARS is a method for confirming lipid peroxidation, in which the degree of lipid peroxidation can be confirmed by measuring that MDA and TBA (thiobarbituric acid) combine to form an MDA-TBA product.
Particularly, ob/ob mice (leptin deficient C57B/6 mice) were used as experimental animals, and 10 mpk or 100 mpk of the compound of Example 1 of the present invention was administered for 3 weeks. After administration of the compound, the animals were stunned with CO2 gas and the livers were collected.
Date Recue/Date Received 2021-06-30 After washing the liver tissues with saline, 50 mg was taken and homogenized. Only the lysate was collected separately by centrifugation. The MDA-TBA product formed as a result of the reaction of MDA and TBA
under the acidic condition at 95r was measured with 0D532. The results are shown in Figure 14.
Figure 14 is a graph illustrating the TBARS
(Thiobarbituric acid reactive substance) activity, an oxidative stress index, measured after the administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
Date Recue/Date Received 2021-06-30
As shown in Figure 3, it was confirmed that the NO production was inhibited by the treatment of the compound of Example 1 of the present invention, and the inhibitory effect of the NO production was increased as the treatment concentration was increased, but the compound of Example 1 of the present invention showed no significant cytotoxicity.
<2-2> Measurement of inflammatory response-related cytokine gene expression In RAW264.7 macrophages activated by treatment of LPS, the expressions of inflammatory cytokine mRNA and protein are increased. Inflammatory cytokines are known to activate macrophages and mediate acute and chronic inflammatory responses.
Therefore, investigating the inhibition of cytokine mRNA and Date Recue/Date Received 2021-06-30 protein secretion by LPS stimulation is important for the development of anti-inflammatory drugs.
Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 1 x 105 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours.
The Raw 264.7 cells were treated with the compound of Example 1 at the concentration of 1 or 10 pM. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. After removing the medium, the cells were washed with PBS. After detaching the cells using 0.1% trypsin-EDTA, the cells were collected by centrifugation. RNA was isolated from the cell precipitation using Trizole reagent. The amount of the isolated RNA was quantified by measuring absorbance at 260 nm. Real-time polymerase chain reaction was performed using a real-time PCR machine (ABI 7500 fast-real time PCR, Applied Biosystem, USA) by mixing about 100 ng of RNA with Verso SYBR Green 1-Step gRT-PCR Low ROX Mix according to the manufacturer's manual.
The genes used for real-time polymerase chain reaction were obtained from Bioneer. The polymerase reaction was carried out at 50r for 15 minutes and at 95r for 15 minutes, followed by denaturation at 95r for 15 seconds, annealing at 60r for 15 seconds, Date Recue/Date Received 2021-06-30 polymerization at 72r, 40 cycles from denaturation to polymerization. The results are shown in Figure 4.
Figure 4 is a graph illustrating the effect of the compound of Example 1 of the present invention on the expression of the inflammatory response-related cytokine IL-6 gene.
<2-3> Measurement of inflammatory response-related protein expression In order to measure the anti-inflammatory effect of the novel isoquinoline derivative of the present invention, an experiment was performed as follows.
In Raw 264.7 macrophages, the inflammatory proteins interleukin-6 (IL-6) and interleukin-lbeta (IL-1p) were secreted out of the cells due to the regulation of inflammatory response by LPS treatment.
This experiment is a method to evaluate the anti-inflammatory activity by measuring the amount of inflammatory proteins secreted after the regulation of the inflammatory response caused by LPS using an enzyme-linked immunosorbent assay (ELISA).
Particularly, Raw 264.7 mouse macrophages were aliquoted in a 96-well plate at the density of 1 x 105 cells/well and stabilized in a 37r, 5% CO2 incubator for 24 hours. The Raw 264.7 cells were treated with the compound of Example 1 at the concentrations of Date Recue/Date Received 2021-06-30 0.1, 1 and 10 pM. After 1 hour, the cells were treated with 1 ug/ml of LPS and cultured for 24 hours. After taking only the cell culture medium, centrifugation was performed at 13,000 rpm for 5 minutes to take only the supernatant. The secreted Interleukin was quantified using a commercially available kit from Elabscience according to the manufacturer's manual.
According to the method, the cell culture solution was dispensed into the provided wells (100 pl/well), and then incubated at 37r for 90 minutes. The culture medium was removed and 100 pl of a biotin-conjugated selective antibody was reacted at 37r for 1 hour, and then washed three times with a washing solution.
Thereafter, 100 pl of a solution labeled with horseradish peroxidase (HRP) was reacted at 37r for 30 minutes, and then washed 5 times with a washing solution. After adding 90 pl of a solution containing a HRP-specific substrate, incubated at 37r for 15 minutes. The reaction was terminated by adding 90 pl of a termination solution, and the absorbance was measured at 450 nm. The experimental results are shown in Figure 5.
Figure 5 is a set of graphs illustrating the effect of the compound of Example 1 of the present invention at the concentrations of 0.1, 1, and 10 pM
Date Recue/Date Received 2021-06-30 on the secretion of the inflammatory response-related proteins IL-6 and IL-1p.
<2-4> Evaluation of whitening effect In order to evaluate the whitening effect of the novel isoquinoline derivative of the present invention, an experiment was performed as follows.
Black melanocytes of zebrafish do not migrate to keratinocytes, but rather exist in melanocytes. When observing the regeneration of melanin pigment, after inhibiting the formation of melanin pigment, it can be investigated by limiting it to the melanocyte generation pathway, and it is easy to observe the melanin synthesized in the initial stage of development. Therefore, zebrafish is more useful for the study of melanin pigment changes compared to other animal models (Logan DW, Burn SF, Jackson IJ. (2006) Regulation of pigmentation in zebrafish melanophores.
Pigment Cell Res. 2006 Jun; 19(3):206-13.).
Particularly, zebrafish fertilized eggs 10 hours after fertilization were placed in a 24-well plate (10 eggs/well), and 1 ml of egg water was added to each well of the plate. The compound of Example 1 was added to each well at the concentrations of 0.1 pM and 1 pM, so that the final volume of each well was 2 ml. Then, each 24-well plate was wrapped in foil to block light, Date Recue/Date Received 2021-06-30 and then incubated in a 28r incubator for 22 hours.
At 32 hours after fertilization, in order to photograph the formation of black melanocytes, the chorion of the developing embryo was peeled off using a forcep (Fine Science Tools). After anesthetizing the developing embryo with Tricaine (4 g/L), the embryo was photographed on 3% methyl cellulose. As the equipment for photographing the developing embryo, a LEICA MZ1OF fluorescence microscope, a LEICA DFC425 camera, and Leica Application Suite software (v4.5) were used. In all the experimental procedures, egg water sterilized after dissolving 60 mg/L of sea salt (Sigma-Aldrich, S9883) in tertiary distilled water was used as a solution for culturing the developing embryo. As a control group, a solvent control group (0.4% DMSO) and phenylthiourea (200 pM PTU), known as a tyrosinase inhibitor, were used (Figure 6A).
In the same manner, experiments were performed with the compound of Comparative Example 1 at the concentrations of 0.5 pM, 1 pM, and 5 pM, and the results are shown in Figure 6B.
On the other hand, in order to confirm the ability of the compound of the present invention to inhibit the melanin synthesis of the already generated melanocytes, the following experiment was performed Date Recue/Date Received 2021-06-30 with juvenile fish 60 hours after fertilization.
Particularly, juvenile fish 60 hours after fertilization were placed in a 24-well plate (10/well), and 1 ml of egg water was added to each well of the plate. The compound of Example 1 was added to each well at the concentrations of 10 pM and 20 pM, so that the final volume of each well was 2 ml. Then, each 24-well plate was wrapped in foil to block light, and then incubated in a 28r incubator for 12 hours.
In order to photograph the formation of black melanocytes, the developing embryo was anesthetized with Tricaine (4 g/L), and then the embryo was photographed on 3% methyl cellulose. The above-mentioned equipment was used for photographing (Figure 6C).
The excellent melanin synthesis inhibitory effect of the novel isoquinoline derivative of the present invention was confirmed. In particular, at 32 hours after fertilization, the synthesis of melanin was inhibited in the group treated with the compound of Example 1 of the present invention at the concentration of 1 pM at a level similar to that in the group treated with PTU. This means that the compound of Example 1 has a 5-fold or more superior activity, compared to the compound of Comparative Date Recue/Date Received 2021-06-30 Example 1 that inhibited the synthesis of melanin at a level similar to that of the PTU-treated group when treated with 5 pM. In addition, at 72 hours after fertilization, compared to the group treated with PTU
at the concentration of 0.2 mM, the compound of Example 1 of the present invention was confirmed to have a superior melanin synthesis inhibitory effect compared to PTU, especially when treated with 20 pM.
<2-5> Evaluation of fatty liver inhibitory effect In order to evaluate the inhibitory efficacy of the novel isoquinoline derivative of the present invention on fatty liver, an experiment was performed as follows using LipidGreen2 staining reagent capable of staining lipid droplets.
The proportion of fat in the normal liver is about 5%, and if more fat is accumulated than this, it is called fatty liver. Fatty liver is largely divided into alcoholic fatty liver caused by excessive drinking and non-alcoholic fatty liver caused by obesity, diabetes, hyperlipidemia, drugs, and the like. The main causes of fatty liver are drinking and obesity. Diseases such as hyperlipidemia with a high blood lipid concentration or diabetes may appear together with fatty liver. Drugs such as Date Recue/Date Received 2021-06-30 corticosteroids (steroids) or female hormones can also cause fatty liver.
Tamoxifen is a nonsteroidal anti-estrogen agent that binds to estrogen receptor a/P by competing with estrogen. It was developed by ICI (UK) and has been used the most as an endocrine therapy for female hormone-dependent cancer since the 1980s. In particular, it is known that hepatocyte necrosis occurs in the zebrafish juvenile fish treated with tamoxifen, and steatosis is known to appear in the adult liver.
Particularly, the zebrafish used in this Experimental Example were juvenile fish 5 days after fertilization. Healthy juvenile fish were placed in a 24-well plate (10/well), and 1 ml of egg water was added to each well of the plate. As a negative control that could not regulate fatty liver, DMSO diluted at 0.4% was exposed to juvenile fish, and tamoxifen (Sigma-Aldrich, 15648) diluted at 5 pM was exposed to juvenile fish to control alcoholic fatty liver. In order to investigate the fatty liver inhibitory efficacy of the compound of Example 1 of the present invention, the compound (0.5 pM, 1 pM and 5 pM) was mixed with 5 pM tamoxifen and exposed to juvenile fish (final volume of each well: 2 ml). The 24-well plate Date Recue/Date Received 2021-06-30 containing the compound was wrapped in foil to block light, and then incubated in a 28r incubator for 22 hours. The plate was washed with egg water 3 times for minutes to remove the compound from each well. For 5 fat-specific staining, LipidGreen2 diluted at 5 pM was exposed to juvenile fish for 30 minutes, and then washed 3 times with egg water for 5 minutes. To evaluate the fatty liver of zebrafish juvenile fish, the developing embryo was anesthetized with Tricaine (4 g/L), and then photographed on 3% methyl cellulose.
As the equipment for photographing the developing embryo, a LEICA MZ1OF fluorescence microscope, a LEICA
DFC425 camera, and Leica Application Suite software (v4.5) were used. For the fluorescence wavelength, a GFP Plants filter set (Excitation 470/40 nm, Emission 525/50 nm) was used. To quantify the liver area and the degree of fat staining of juvenile fish on the image, the area and the fluorescence intensity of the liver part of each image were quantified using ImageJ
1.50i software (National Institutes of Health, USA) and converted into heatmap images. The experimental results are shown in Figures 7 and 8.
Figure 7 is a set of general microscope images, fluorescence microscope images and heatmap conversion images observed after the treatment of DMSO, tamoxifen Date Recue/Date Received 2021-06-30 and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization.
Figure 8 is a set of graphs illustrating the results of quantification of liver area (top) and fluorescence intensity (bottom) on the zebrafish juvenile fish images observed after the treatment of DMSO, tamoxifen and the compound of Example 1 of the present invention in zebrafish juvenile fish 5 days after fertilization using ImageJ 1.50i softwear (National Institutes of Health, USA) (The p values are the t-test results for each experimental group compared to the tamoxifen-treated group. *p 0.01, **p 0.001).
In Figure 7, the white dotted lines on the general microscope image and the fluorescence microscope image and the black dotted line on the heatmap conversion image indicate the liver part of the same juvenile fish. In particular, in the heatmap conversion image, a red color indicates the strong fluorescence intensity, and a blue color indicates the weak fluorescence intensity.
As shown in Figure 7, as a result of LipidGreen2 fat staining, it was confirmed that the fatty liver regulated by tamoxifen was restored to the normal Date Recue/Date Received 2021-06-30 level in the group treated with the compound of Example 1 of the present invention.
In Figure 8, the upper part is a graph statistically confirming that the liver area of the juvenile fish of the group treated with the compound of Example 1 of the present invention or tamoxifen was maintained at the liver area level of normal juvenile fish, and the lower part is a graph confirming that the fluorescence intensity of the juvenile fish of the group treated with the compound of Example 1 of the present invention was decreased to the normal level compared to the fluorescence intensity of the juvenile fish of the group treated with tamoxifen. From the above results, it was confirmed that the compound of Example 1 can be effectively used for the treatment or amelioration of fatty liver.
<Experimental Example 3> Toxicity test <3-1> Non-selective general cytotoxicity test In order to evaluate the non-selective cytotoxicity of the compound of Example 1 of the present invention in various cell lines, the following experiment was performed.
In this experiment, the cell lines derived from different species, VERO (African green monkey kidney cell line), HFL-1 (human embryonic lung cell line), Date Recue/Date Received 2021-06-30 L929 (mouse fibroblast cell line), NIH 313 (mouse embryonic fibroblast cell line), CHO-K1 (Chinese hamster ovary cell line) and HMV-II (human malignant melanoma cell line), were used.
Particularly, VERO, HFL-1, L929 and NIH 313 cell lines were cultured in DMEM, CHO-K1 was cultured in RPMI1640 medium, and HMV-II was cultured in DME/F-12 medium. 10% FBS (Fetal Bovine Serum) and 100 pg/mL of antibiotics were added to each medium. The cells were acclimatized and cultured in a humidified 37r 5% CO
incubator, washed with PBS (phosphate buffer solution) at the time of growth that occupies 70-80% of the culture dish every 2-3 days, and then subcultured by treating with Trypsin-EDTA (Gibco, USA).
The cells used in this Experimental Example were aliquoted into a 96-well culture plate at the density of 15,000 - 25,000 cells/well, and then acclimatized and cultured in a humidified 37r 5% CO2 incubator for 24 hours. The compound of Example 1 of the present invention was prepared to be 10 mM using DMSO, and diluted sequentially. Each cell line was treated with the compound at the final concentration, and cultured for 24 hours. The cell viability was measured according to the standard method using a Cyto XTM cell viability assay kit (LPS solution). 10 pl of a Date Recue/Date Received 2021-06-30 chromogenic reagent was added to each well and incubated for 2 hours in a humidified 37r 5% CO2 incubator, followed by measuring the absorbance at 450 nm. The survival rate was measured by calculating the ratio of the absorbance changed compared to the absorbance measured in the group treated with DMSO
alone. The results are shown in Figure 9.
Figure 9 is a graph illustrating the cell viability of VERO, HFL-1, L929, NIH 3T3, CHO-K1 and HMV-II cell lines according to the concentration of the compound of Example 1 of the present invention treated.
As shown in Figure 9, the compound of Example 1 of the present invention had no significant toxicity in all cell lines up to 10 pM, and showed less than 50% cytotoxicity at the maximum test concentration of 100 pM.
<3-2> Cardiotoxicity test In order to evaluate the possibility of inducing cardiotoxicity of the compound of Example 1 of the present invention in vivo, the inhibitory potential to the hERG (human ether-a-go-go related gene) IC+ channel protein, known as a main cause of arrhythmias, was tested.
First, a ligand binding test was performed to Date Recue/Date Received 2021-06-30 evaluate the binding force of the compound of Example 1 binding to the hERG channel protein in vitro. A
biological membrane containing the hERG channel protein was aliquoted in a 384-black well plate (10 p1/well) at room temperature, and DMSO, E-4031 (positive control), and the compound of Example 1 prepared to be 4 times the final test concentration were added thereto (5 pl/well). A tracer material with a fluorescent material attached to astemizole, known as a selective binding substance to the hERG channel protein, was dispensed into a mixture of the two solutions (5 pl/well), and then incubated for 2 hours at room temperature where light was blocked. In order to excite the tracer material included in the reaction solution, the light of 530 nm was irradiated and the light of 585 nm returned back was measured by the polarization method. In this experiment, the high polarization value by the tracer material means a lot of binding between the hERG protein and the tracer.
Conversely, the low polarization value indicates a lot of binding between the hERG protein and the test material. The binding force of the test material to the hERG protein was expressed as the inhibition rate (%) compared to the group treated with DMSO.
Next, in order to evaluate the activity of the Date Recue/Date Received 2021-06-30 hERG channel protein using an electrophysiological method, a patch clamp test was performed. The activity of the hERG channel protein was measured using the HEK-293 cell line overexpressing the hERG channel protein. The cells were acclimatized and cultured in a humidified 37r 5% CO2 incubator, washed with PBS
(phosphate buffer solution) at the time of growth that occupies 70-80% of the culture dish every 2-3 days, and then subcultured by treating with Trypsin-EDTA.
For the test, 2 x 105 cells were aliquoted in a 60 mm cell culture dish, and then cultured in a humidified 5% CO2 incubator for 48 hours. The cultured cells were detached by treating Trypsin-EDTA (Gibco, USA), and the flow of K+ by the hERG channel protein was measured by applying an automated patch clamp equipment (PatchXpress, Molecular Device).
The experimental results of the two experiments above are shown in Figure 10.
Figure 10 is a graph illustrating the inhibition of the binding and activity of the hERG channel protein by the compound of Example 1 of the present invention, presented by ligand binding and patch clamp curves, respectively.
As shown in Figure 10, the inhibition of the binding and activity of the hERG channel protein by Date Recue/Date Received 2021-06-30 the compound of Example 1 of the present invention was found to be about 10% at 10 pM. These results are significantly less than the 50% inhibition rate at 10 pM, which is a standard for judging general toxicity, and thus, it is determined that the compound of Example 1 of the present invention has a low possibility of inducing cardiotoxicity by inhibiting the hERG channel protein in vivo.
<3-3> Skin toxicity test In order to evaluate the skin toxicity that may be induced upon skin contact of the compound of Example 1 of the present invention, the following experiment was performed using the artificial skin prepared with a structure similar to the skin of a living body.
Particularly, the experiment was performed according to OECD Guideline for the Testing of Chemicals No. 439, OECD (2010) and the method recommended by the manufacturer (Tegoscience).
First, the artificial skin cultured in agarose medium was transferred to a 12-well cell culture plate, to which culture medium was added, followed by culture in a humidified 37 C 5% CO2 incubator for one day. The medium on the artificial skin culture surface was eliminated, and 90 pl of the compound of Example 1 Date Recue/Date Received 2021-06-30 of the present invention diluted with PBS was evenly applied to the skin surface, followed by incubation at room temperature for 15 minutes. The cell surface was washed twice with 10 ml of PBS, and a fresh culture medium was added, followed by incubation in a humidified 37r 5% CO2 incubator for 42 hours. In order to measure the viability of the skin, the artificial skin was transferred to a 12-well plate containing 2 ml of MTT solution (0.3 mg/ml), followed by culture for 3 hours. The stained artificial skin tissue was taken and transferred to a tube containing 500 pl of 0.04 N-isopropanol, and then incubated with shaking for 4 hours to decolorize. The solution was centrifuged at 13,000 rpm for 5 minutes, 100 pl of the supernatant was transferred to each well of a 96-well plate, and absorbance was measured at 570 nm. The results are shown in Figure 11.
Figure 11 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, SDS, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MTT stained on the artificial skin tissue using isopropanol.
As shown in Figure 11, a significant decrease of the MTT color development due to necrosis of the skin Date Recue/Date Received 2021-06-30 tissue was observed in the control group treated with 5% SDS, whereas in the group treated with the compound of Example 1 of the present invention, there was no significant decrease of the survival rate up to 20 pM, and a slight decrease of the survival rate was confirmed only in the group treated with the compound at the concentration of 50 pM, the maximum concentration.
<3-4> Ocular toxicity test In order to evaluate the ocular toxicity that may be induced upon ocular exposure of the compound of Example 1 of the present invention, the following experiment was performed using the cultured artificial cornea.
The artificial corneal tissue cultured in agarose medium was transferred to a 12-well cell culture plate, to which culture medium was added, followed by culture in a humidified 37r 5% CO2 incubator for one day. The medium on the artificial cornea culture surface was eliminated, and 30 pl of the compound of Example 1 of the present invention diluted with PBS
was evenly applied to the cornea surface, followed by incubation at room temperature for 30 minutes. The cell surface was washed twice with 10 ml of PBS, and a fresh culture medium was added, followed by incubation Date Recue/Date Received 2021-06-30 in a humidified 37 C 5% CO2 incubator for 30 minutes.
In order to measure the viability of the cornea, the artificial cornea was transferred to a 12-well plate containing 2 ml of MTT solution (1 mg/ml), followed by culture for 3 hours. The stained artificial corneal tissue was taken and transferred to a tube containing 1.5 ml of isopropanol, and then incubated with shaking to decolorize. The solution was centrifuged at 13,000 rpm for 5 minutes, 100 pl of the supernatant was transferred to each well of a 96-well plate, and absorbance was measured at 570 nm. The results are shown in Figure 12.
Figure 12 is a graph illustrating the survival rate of the groups treated with a vehicle, ARB, acetic acid, and 10, 20 and 50 pM of the compound of Example 1 of the present invention, calculated based on the absorbance measured after eluting MTT stained on the artificial corneal tissue using isopropanol.
As shown in Figure 12, a significant decrease of the MTT color development due to necrosis of the corneal tissue was observed in the control group treated with 10% acetic acid, whereas in the group treated with the compound of Example 1 of the present invention, there was no significant decrease of the survival rate up to 50 pM, the maximum concentration.
Date Recue/Date Received 2021-06-30 <3-5> Evaluation of ALT (aminotransferase) activity, a liver damage index In order to evaluate the effect of the compound of Example 1 of the present invention on the activity of a liver damage index, the activity of ALT
(aminotransferase), a liver damage index, was analyzed in ob/ob mice, an obesity-controlled rodent model.
ALT is alanine aminotransferase, which is an enzyme that helps amino acid exchange between keto acids and amino acids. When the enzyme leaked into the blood during cell damage is measured, the enzyme is elevated in liver damage such as viral hepatitis.
Particularly, ob/ob mice (leptin deficient C57B/6 mice) were used as experimental animals, and 10 mpk or 100 mpk of the compound of Example 1 of the present invention was administered for 3 weeks. After administration of the compound, the animals were stunned with CO2 gas and the livers were collected.
After washing the liver tissues with saline, 50 mg was taken and homogenized. Only the lysate was collected separately by centrifugation. The lysate and the substrate for enzyme reaction were added thereto, and the fluorescence value was measured at 535/587 nm. The results are shown in the graph of Figure 13.
Figure 13 is a graph illustrating the ALT
Date Recue/Date Received 2021-06-30 (aminotransferase) activity, a liver damage index, measured after the administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
<3-6> Evaluation of oxidative stress In order to evaluate the oxidative stress of the compound of Example 1 of the present invention, the activity of TBARS (Thiobarbituric acid reactive substance), an oxidative stress index, was analyzed in ob/ob mice, an obesity-controlled rodent model.
Lipid peroxidation is a well-known mechanism of cell damage and is used as an index of oxidative stress. Measurement of TBARS is a method for confirming lipid peroxidation, in which the degree of lipid peroxidation can be confirmed by measuring that MDA and TBA (thiobarbituric acid) combine to form an MDA-TBA product.
Particularly, ob/ob mice (leptin deficient C57B/6 mice) were used as experimental animals, and 10 mpk or 100 mpk of the compound of Example 1 of the present invention was administered for 3 weeks. After administration of the compound, the animals were stunned with CO2 gas and the livers were collected.
Date Recue/Date Received 2021-06-30 After washing the liver tissues with saline, 50 mg was taken and homogenized. Only the lysate was collected separately by centrifugation. The MDA-TBA product formed as a result of the reaction of MDA and TBA
under the acidic condition at 95r was measured with 0D532. The results are shown in Figure 14.
Figure 14 is a graph illustrating the TBARS
(Thiobarbituric acid reactive substance) activity, an oxidative stress index, measured after the administration of a vehicle, a positive control (10 mpk Rosi), and the compound of Example 1 of the present invention (10 mpk and 100 mpk), respectively, in an obesity-controlled rodent model.
Date Recue/Date Received 2021-06-30
Claims (10)
1. A compound represented by formula 1 below or a pharmaceutically acceptable salt thereof:
[Formula 1]
Fe z-t C, (In formula 1, 1R.1 is nonsubstituted or substituted phenyl, wherein the substituted phenyl is substituted with one or more substituents selected from the group consisting of halogen and CF3;
any one of X and Y is CH, and the other is N; and Z is S(0)).
[Formula 1]
Fe z-t C, (In formula 1, 1R.1 is nonsubstituted or substituted phenyl, wherein the substituted phenyl is substituted with one or more substituents selected from the group consisting of halogen and CF3;
any one of X and Y is CH, and the other is N; and Z is S(0)).
2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the X is CH and the Y is N.
3. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by formula 1 is any one Date Recue/Date Received 2021-06-30 selected from the group consisting of the following compounds:
1-((4-fluorophenyl)sulfinyl)isoquinoline;
4-((4-fluorophenyl)sulfinyl)quinoline;
1-((2,4-difluorophenyl)sulfinyl)isoquinoline;
1-((4-chlorophenyl)sulfinyl)isoquinoline; and 1-((4-(trifluoromethyl)phenyl)sulfinyl)isoquinoline.
1-((4-fluorophenyl)sulfinyl)isoquinoline;
4-((4-fluorophenyl)sulfinyl)quinoline;
1-((2,4-difluorophenyl)sulfinyl)isoquinoline;
1-((4-chlorophenyl)sulfinyl)isoquinoline; and 1-((4-(trifluoromethyl)phenyl)sulfinyl)isoquinoline.
4. A pharmaceutical compostion for inhibiting or treating inflammatory disease comprising compound or the pharmaceutically acceptable salt thereof of claim 1 as an effective ingredient.
5. The pharmaceutical composition according to claim 4, wherein the inflammatory disease is selected from the group consisting of inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, dermatitis, atopic dermatitis, ophthalmitis, keratitis, hepatitis and non-alcoholic hepatitis.
6. A Pharmaceutical composition for inhibiting or treating fatty liver comprising the compound or the Date Recue/Date Received 2021-06-30 pharmaceutically acceptable salt thereof of claim 1 as an effective ingredient.
7. A pharmaceutical compositon for preventing or treating skin hyperpigmentation disease comprising the compound or the pharmaceutically acceptable salt thereof of claim 1 as an effective ingredient.
8. The pharmaceutical composition according to claim 7, wherein the disease is a skin disease caused by melanin overproduction.
9. A pharmaceutical compositon for inhibiting melanogenesis in a certain area of a subject comprising the compound or the pharmaceutically acceptable salt thereof of claim 1 as an effective ingredient.
10. The pharmaceutical compositon according to claim 9, wherein the certain area is skin, hair or eye.
Date Recue/Date Received 2021-06-30
Date Recue/Date Received 2021-06-30
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3123732A CA3123732C (en) | 2021-06-30 | 2021-06-30 | Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing in the same as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3123732A CA3123732C (en) | 2021-06-30 | 2021-06-30 | Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing in the same as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3123732A1 true CA3123732A1 (en) | 2022-12-30 |
CA3123732C CA3123732C (en) | 2023-12-19 |
Family
ID=84818791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3123732A Active CA3123732C (en) | 2021-06-30 | 2021-06-30 | Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing in the same as an active ingredient |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3123732C (en) |
-
2021
- 2021-06-30 CA CA3123732A patent/CA3123732C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3123732C (en) | 2023-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107082770B (en) | IRE-1 alpha inhibitor | |
CN102985420B (en) | Cytochrome P 450 inhibitors and application thereof | |
CN110431130A (en) | Multi-crystalline compounds and its purposes | |
RU2378250C2 (en) | Nonsteroid modulators of androgen receptor, method of production, pharmeceutical composition thereof and use | |
JP2023030022A (en) | Fibrotic treatment | |
KR102334943B1 (en) | Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient | |
CN108250058A (en) | PPAR agonists and its purposes in treatment senile dementia and other diseases | |
CA3119313A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
WO2021213518A1 (en) | Compound for preventing or treating lipid metabolism-related diseases | |
CN107151233B (en) | Hydrazone-containing pyrimidine derivative and application thereof | |
WO2007052882A1 (en) | Pyridine thiazole carboxamide derivatives, the preparation method thereof, and the composition for skin whitening containing the same | |
CA3123732C (en) | Novel isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing in the same as an active ingredient | |
CN113015731A (en) | Photoprotective compositions comprising compounds derived from malassezia and/or chemical analogues thereof | |
US11878013B2 (en) | Isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient | |
CN111253246B (en) | Acyl acid derivative and preparation method and medical application thereof | |
KR20240047995A (en) | Compositions, formulations, and methods for hair treatment | |
TWI308148B (en) | Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component | |
JP2018516971A (en) | Beta-naphthoisoflavone, composition containing the same and use thereof | |
CN104203945B (en) | 1, 4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof | |
DE60005368T2 (en) | Thienopyran-carboxamide DERIVATIVES | |
TW401415B (en) | Enantiomerically pure (+)-liarozole | |
WO2021009768A1 (en) | An oral pharmaceutical composition for alpha- amylase inhibition | |
KR100889460B1 (en) | Composition for enhancing melanogenesis in hair containing gdnf, method for enhancing melanogenesis in hair using gdnf, and method for screening hair-melanogenesis enhancer using gdnf expression level | |
CN108904481A (en) | O-hydroxylate chalcone analog is preparing the application in anti-oxidation medicine | |
WO2023083291A1 (en) | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis |